HDR brachytherapy as monotherapy for low risk prostate cancer: dosimetric and clinical evaluation by Lopes, Ana Rita Gomes
Universidade de Lisboa
Faculdade de Cieˆncias
Departamento de Fı´sica
HDR Brachytherapy as monotherapy for low risk prostate
cancer: dosimetric and clinical evaluation
Ana Rita Gomes Lopes
Mestrado Integrado em Engenharia Biome´dica e Biofı´sica
Perl em Radiac¸o˜es em Diagno´stico e Terapia
Dissertac¸a˜o orientada por:
Dr. Inger-Karine Kolkman-Deurloo
Prof. Dr. Luis Peralta
2016

Resumo
Na Europa, o cancro da pro´stata e´ um dos tumores malignos mais comum nos homens. A idade me´dia no
diagno´stico e´ de 65 anos, raramente sendo este tumor diagnosticado antes dos 50 anos. Em Portugal, segundo
a Direc¸a˜o Geral de Sau´de, a taxa de incideˆncia de cancro da pro´stata e´ aproximadamente 82 casos por 100 000
habitantes. Na Holanda, 11 158 novos casos de cancro da pro´stata sa˜o diagnosticados por ano.
A radioterapia tem vindo a ocupar um lugar de elevada importaˆncia no que diz respeito a tratamento de foro
oncolo´gico. Novas te´cnicas de radioterapia com intuito curativo do cancro da pro´stata teˆm surgido ao longo
dos anos. No entanto, nos u´ltimos anos, a braquiterapia de alta taxa (HDR) tem vindo a ocupar um lugar
importante no tratamento de tumores malignos na pro´stata. Inicialmente, esta terapia foi combinada com a
radioterapia externa convencional, funcionando como reforc¸o de radiac¸a˜o na pro´stata, vulgarmente conhecido
pelo termo ingleˆs “boost”. Este tratamento combinado e´ administrado em pacientes de interme´dio-alto risco
de cancro de pro´stata. Ao longo dos anos, HDR braquiterapia tem vindo a ser bastante utilizada como terapia
u´nica em pacientes de baixo risco, evitando deste modo procedimento mais radicais como a prostatectomia
radical.
A braquiterapia de alta taxa e´ caracterizada por uma distribuic¸a˜o de dose bem conformada na pro´stata e por
ter “dose fall-o” acentuado. Assim, esta te´cnica salvaguarda os o´rga˜os de risco (bexiga e reto) de uma forma
mais ecaz do que outras te´cnicas de radioterapia, tais como a radioterapia de intensidade modelada (IMRT)
ou radioterapia conformada tridimensional (3D RT). No ErasmusMC – Cancer Institute (Roterda˜o, Holanda)
este tratamento e´ executado em 4 sesso˜es de 9.5Gy (38Gy) cada, separadas de um intervalo mı´nimo de 6
horas. O doente e´ internado por 2 dias, e tem alta me´dica no nal do segundo dia. O procedimento clinico
da implementac¸a˜o das agulhas e´ guiada por ultrassons e e´ indolor, uma vez que o paciente esta´ sob o efeito
de anestesia epidural. Antes de cada sessa˜o de tratamento, uma imagem de raios-x lateral e´ adquirida por
forma a vericar possı´veis desvios das agulhas na direc¸a˜o caudal. Os desvios superiores 3 mm sa˜o corrigidos
de modo a evitar o risco de subdosagem na pro´stata e/ou sobredosagem nos o´rga˜os de risco.
A braquiterapia da alta taxa como terapia u´nica e´ conhecida por ter uma incideˆncia de toxicidades agudas
nos tecidos reduzida e por ter um controlo bioquı´mico bastante elevado. Contudo, existem alguns efeitos
secunda´rios apo´s o tratamento, tais como a retenc¸a˜o urina´ria aguda (AUR) e o sangramento retal (RB). Estes
efeitos secunda´rios, embora transito´rios, provocam um acre´scimo de ansiedade e desconforto no paciente
afetando as suas rotinas dia´rias sendo importante investigar as possı´veis causas.
Nesta tese, o principal objetivo e´ investigar quais sa˜o os fatores associados a estes dois efeitos secunda´rios de
forma a minimiza´-los e a melhorar a qualidade de vida dos pacientes apo´s o tratamento. Para cada um dos
efeitos secunda´rios, ferramentas estatı´sticas apropriadas, tais como Mann-Whitney teste, Chi-Square teste e
Regressa˜o Logı´stica uni-varia´vel e multivaria´vel, foram usadas para comparar paraˆmetros dosime´tricos (dose-
volume histograms - DVH) e clı´nicos (idade, IPSS - International Prostate Symptom Score, volume da pro´stata,
etc.) entre o grupo de casos (14 AUR e 15 RB) e o grupo de pacientes considerado como controlo (28 no-AUR
e 30 no-RB).
Dos va´rios paraˆmetros clı´nicos e dosime´tricos em estudo, apenas o uxo urina´rio medido antes do trata-
mento (Baseline urinary ow - Qmax) inferior 10 ml/s e 25% do volume da bexiga recebendo doses (Bexiga
i
D25) superiores a 30-40% da dose prescrita foram os principais fatores associados a um elevado risco de de-
senvolvimento de retenc¸a˜o urina´ria aguda com a necessidade de arga´lia apo´s o tratamento. Este resultado
foi conrmado quando se analisaram estas varia´veis novamente, na base de dados completa dos pacientes
tratados com HDR braquiterapia (210 pacientes). Outro paraˆmetro, uretra membranosa D0.5cc≥ 55% da dose
prescrita, mostrou-se estar estatisticamente associado a um aumento do risco de desenvolvimento de retenc¸a˜o
urina´ria aguda apo´s o tratamento. No entanto, este resultado necessita de ser conrmado em estudos futuros.
Para ale´m disso, por forma a conrmar os valores limite de dose para os quais o risco de desenvolvimento
de AUR e´ elevado, foram utilizadas as curvas ROC (Receiver Operating Characteristic Curve). Este me´todo
provou que Qmax < 10 ml/s e bexiga D25 ≥ 30-40% estimam bem o risco associado ao desenvolvimento de
retenc¸a˜o urina´ria aguda com uma a´rea abaixo da curva ROC superior a 0.7.
No que diz respeito ao segundo efeito secunda´rio, RB, os resultados sa˜o inconclusivos, quer em termos de
paraˆmetros dosime´tricos quer em termos de varia´veis clı´nicas. Embora alguns paraˆmetros dosime´tricos se
tenham mostrado estar estatisticamente relacionados com o desenvolvimento de sangramento retal, estes na˜o
teˆm signicado clinico relevante. PTV volume ≥ 55 cc e Hipertensa˜o mostraram-se estar estatisticamente
associados ao risco de RB mas essa relac¸a˜o na˜o e´ dedigna, uma vez que PTV volume≥ 55 cc na˜o se mostrou
estar estatisticamente associado ao RB na base de dados de 210 pacientes e na˜o existem dados que indiquem
que os pacientes hipertensos esta˜o a ser corretamente medicados e/ou que seguem o tratamento prescrito.
Em suma, este estudo e´ o primeiro estudo retrospetivo sobre HDR braquiterapia como terapia u´nica com
resultados bastante promissores. Os resultados sugerem que se deve limitar a dose entregue a 25% do volume
da bexiga, a 30%-40% da dose prescrita, e que Qmax deve ser incluı´do na lista de crite´rios de selec¸a˜o de
pacientes para o tratamento. Este projeto, sugere ainda que se deve ter em conta a dose recebida em 0.5cc de
volume da uretra membranosa, mas este resultado esta´ sujeito a futuras investigac¸o˜es.
Palavras-chave: HDR braquiterapia, cancro da pro´stata, retenc¸a˜o urina´ria aguda, sangramento retal, avaliac¸a˜o
dosime´trica e clı´nica
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Abstract
Prostate cancer is the most common cancer in Europe for males. In Portugal, it is estimated that prostate
cancer has an incidence of 82 cases per 100 000 inhabitants. In the Netherlands, 11 158 new cases of prostate
cancer are diagnosed each year. For the past years, High-Dose Rate Brachytherapy (HDR BT) as monotherapy
has been playing an important role in treatment of prostate cancer. is type of radiotherapy has excellent
results because of its highly conformal dose distribution within the prostate with a rapid dose fall-o outside,
sparing the organs at risk. Even so, side eects, such as acute urinary retention (AUR) and rectal bleeding
(RB), occur aer treatment.
In this thesis, predictive factors for AUR and RB were investigated in order to nd and/or improve new
treatment constraints to avoid and/or minimize the occurrence of these side eects, consequently, improving
patient’s quality of life aer treatment. In two investigations, dose-volume histograms (DVH) and clinical
parameters were compared, between cases (14 AUR and 15 RB) and controls (28 no-AUR and 30 no-RB). In
both projects, appropriate statistical tools, such as Chi-Square test, Mann-Whitney test and Univariate and
Multivariate Logistic Regression, were used.
In AUR project, baseline urinary ow (Qmax) < 10 ml/s and 25% of bladder volume receiving doses (bladder
D25) ≥30-40% of prescribed dose were the most important risk factors for AUR. ese two parameters were
aerwards conrmed as risk factors for AUR in a large dataset of 210 patients and also through the Receiver
Operating Characteristic Curve (ROC). Another dosimetric parameter, urethra membranous D0.5cc ≥ 55% of
PD, was statistically associated with the increased risk of AUR. However, this result needs to be conrmed in
future studies.
In RB project, either in terms of DVH or clinical parameters, the results were inconclusive. Some DVH pa-
rameters of cranial rectum were statistically correlated with RB but without clinical relevance. PTV volume
≥ 55 cc and Hypertension were statistically signicant but they did not show a clear relationship with RB.
In summary, this rst HDR BT retrospective study suggests that bladder D25 and Qmax could be considered
during selection and treatment patients to minimize AUR.
Keywords: HDR Brachytherapy, prostate cancer, acute uninary retention, rectal bleeding, dosimetry and
clinical evaluation.
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Chapter 1
Brachytherapy Introduction
1.1 Historical Background
e beginning of radiation treatment started when Wilhelm Ro¨ntgen discovered the x-rays in Novem-
ber 1895, and shortly aerwards, Henri Becquerel accidentally exposed a photographic plate to uranium in
1896, identifying the phenomenon of emied radiation. Some years later, Becquerel himself experienced the
eects of radiation exposure by carrying a tube containing radium chloride in his vest pocket.
e rst clinical applications belonged to Danlos and Bloch (1901) in Paris, and Abbe´ (1904) in New
York. e basic principles of systematic use of radiation were established somewhat later aer World War I
in the Radium Hemmet in Stockholm, e Memorial Hospital in New York and the Radium Institute in Paris.
Nowadays, there are several types of radiation treatment but at that time only so called Brachytherapy
existed. is way, the term Brachytherapy (BT) can be dened as a near therapy with radiation sources being
placed directly on, in or through the area of interest that is to receive a high radiation dose, i.e. the target.
erefore, Brachytherapy has been used from very early days of radiation discovery. Several types of
sources have been used until now. One of the most important during the rst two decades of the twentieth
century was 226Ra. At that time it was necessary to create a set of rules related to the arrangement of the
radioactive sources (geometry paerns), denition of the source strength, spacing and treatment time in the
treatments. ese criteria were developed by three important institutions in Stockolm (1914), Paris (1919) and
Manchester (1967) for intracavitary treatments.
Two other important moments in the history contributed to the development of this area: the disco-
very of articial radioactivity and the development of remote aerloading devices, which provided improved
radiation protection.
ere are 3 dierent types of BT: LDR BT (low-dose rate), HDR BT (high-dose rate) and PDR (Pulsed-
dose rate). e main dierence between these 3 types is the method of delivery:
• LDR BT: continuously dose delivery using LDR source;
• HDR BT: dose is delivered in 1 or few fractions using HDR source;
• PDR BT: dose is delivered in many fractions separated 1 to few hours.
LDR BT was the technique that was implemented using 192Ir, for temporary implants, and more re-
cently 125I, for permanent implants, as radioactive sources. During the last decades this kind of BT is mainly
used for permanent implant technique for prostate cancer. Due to aerloading devices development, HDR
BT started to grow and nowadays it is the most used technique to treat several kinds of tumours such as
gynaecology and prostate cancer.
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1.2 Technical and Physical Aspects of Brachytherapy
As I said before, in the rsts years of BT, the radioactive sources were manually implanted into the
tumour, thereby subjecting the physician and other medical personnel to unwanted radiation exposure. At the
middle of the last century, the Remote Aerloaders (RALs), which is a computer-driven system that transports
the radioactive source from a shielded safe into the applicator placed in the patient and back to its safe,
minimized the radiation exposure to personnel.
HDR BT, administering discrete fractions in a temporary implant, have become common in treatment
of gynaecological, breast and prostate cancer. Nowadays, this type of radiotherapy is very useful because,
as monotherapy or combined with External Beam Radiotherapy (EBRT), it allows a good growth control of
tumour cells.
Components of an HDR RAL (see gure 1.1)
HDR RAL is built by dierent components which these will explained in following items.
• Shielded safe and radioactive source: a stepping source usually consist of 192Ir with an activity up to
370 Bq to provide a dose rate up to 700cGy/min at 1 cm from the source. To house his highly radioactive
source, a shielded safe made of tungsten or depleted uranium of sucient thickness to provide enough
radiation shielding is an integral part of the treatment unit.
• Source drive mechanism and transfer tubes: there are two dierent cables: check cable (without
radioactive source inside) and source cables (with radioactive source). when the treatment starts, the
check cable stepper motor drives the check cable to the programmed length plus a couple of millimetres
to verify the integrity of the system. Aer this procedure, the source drives through the transfer tubes to
the plastic needles to perform the treatment (with certain dwell positions and weights for each needle).
Aer the procedure in the rst needle, the source goes to the house shielding and drives again for the
second needle. is procedure is repeated for all needles.
• Indexer: is the part of RAL that directs the check source cable from the exit of the safe to one of the
exit ports from the unit called as channels. It uses one channel for each needle and the connections
between the channels and needles are the transfer tubes. Most machines have up to 40 channels.
• Treatment Control Station: this part allows the user to select the dwell positions and dwell times
to be used in each channel. Nowadays, the data from a treatment planning system is imported for the
systems and radiation delivered according to the treatment plan.
• Treatment Control Panel: the treatment control station transfers the data to the treatment control
panel aer the treatment is started. Also, this panel has an interrupt buon and an emergency buon.
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(a) A schematic gure of the head of
RAL and transfer tubes (Elekta). (b) A schematic gure of the head components of RAL (Elekta).
(c) Complete conguration of devices composing the remote aerloader
machine. 1) Treatment Delivery Unit; 2) Treatment Control Station; 3)
Treatment Control Panel. Courtesy of Nucletron.
Figure 1.1: Figures of remote aerloaders machines. Taken from [2, 3].
e currently available HDR RALs use stepping-source technology, consisting of a singles source at
the end of a cable that moves the source in steps through the applicators placed in the treated volume. e
important advantage of this stepping source is that the dose distribution can be modied by altering the
source positions and the dwell times (i.e., the time spent at each source position). Figure 1.2 illustrates the
dwell positions and the dose distribution due to a stepping single source.
(a) A schematic gure of source and your dwell
positions.
(b) Autoradiograph image of dose
distribution produced by a single
source in a single catheter.
Figure 1.2: Dwell positions and dose distribution. Taken from [4].
e 3D dose distribution around a source is determined by the following factors:
• e inverse square law: the particle uence around a point source in vacuum falls of with the square
of the distance to the source.
4 Chapter 1. Brachytherapy Introduction
• e interaction of emied particles with the materials within the source itself and around it.
e dose distribution in tissue is mostly dependent on the type of source (e.g. energy), type of tissue
and dwell times and positions. Figure 1.3 shows the dierence in isodose curves produced by dierent kinds
of sources in phantom.
Figure 1.3: e isodose curves produced by dierent sources. Taken from [5].
Nowadays, the dose calculation formalism is recommended by Task Group 43 [6] of AAPM. It is the
generally accepted method to express the dose distribution around brachytherapy sources.
1.3 Brachytherapy for Prostate Cancer
Interstitial BT with permanent seeds where the activity of source decays for almost zero in some
months (T1/2 = 59 days) or temporary high-dose rate implants where the source only stays inside the
patient for some minutes has received a renewed interest in the last 20 years, mostly because the technological
improvement of ultrasound image guidance and also because of the highly sophisticated precision of this
new technique. e appearance of new radioisotopes also was a good contribution for the development of
brachytherapy.
Prostate cancer has a dierent tumour behaviour, suggesting a low alpha/beta ratio [7, 8] which is
smaller than that of rectum and bladder [9], makes it possible to apply hypofractionation using high fraction
dose to treat PCa. e α/β ratio is the dose where cell killing due to the linear and quadratic components are
equal. In general:
• High value of α/β ratio, the more linear the cell survival curve will be;
• Low value of α/β ratio (i.e. high beta relative to alpha), the more curved the cell survival curve.
So this way is explained why HDR brachytherapy is adequate for prostate cancer. Prostate is more
sensitive to high doses and it has a good tissue response because the proliferation rate of cancer cells is low.
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1.3.1 Target Denition in Prostate Brachytherapy
e target denition in Brachytherapy for prostate cancer is very similar to the target denition for
other types of Radiotherapy. is denition is described below:
• GTV (Gross tumour volume): is the palpable, visible, or clinically demonstrable location and extent of
malignant growth;
• CTV (Clinical target volume): is the volume that contains the GTV and includes subclinical malignant
disease at a certain probability level. (In prostate cancer, this growths goes for capsule and for seminal
vesicles); In this specic technique CTV volume is the whole prostate gland;
• PTV (Planning target volume): the CTV plus one margin includes whole tumour’s movements. For BT
the CTV is equal to PTV because there are no signicant opportunities for set-up errors;
• OAR (Organs at Risk): urethra, rectum, penile bulb and bladder.
Figure 1.4: Graphical representation of the volumes of interest, as dened in ICRU Reports No. 50 and 62. Taken from
Radiation Oncology Physics, chapter 7 [10].
1.3.2 EBRT + HDR BT
EBRT combined with HDR Brachytherapy is beyond the scope of this research topic but several studies
reported that they had good results when combining these two techniques, because with HDR boost they
manage to deliver high doses into the target volume sparing the organs at risk. e HDR boost also has a
radiobiologic advantage gained by hypofractionation schema.
For this type of technique the GEC/ESTRO [11] recommendations have several dose prescriptions for
EBRT as: 45Gy in 25 fractions over 5 weeks, 46Gy in 23 fraction over 4.5 weeks, 35.7Gy in 13 fraction over 2.5
weeks or 37.5 in 15 fractions over 3 weeks. Regarding to the HDR boost, the dose prescription is as: 15Gy in
3 fraction, 11-22Gy in 2 fraction or 12-15Gy in 1 fraction.
1.3.3 HDR BT as monotherapy
HDR BT as monotherapy is associated with low acute toxicity and high biochemical control rates. e
schedules (planning aim) which have been used include: 34Gy in 4 fraction; 36-38 in 4 fractions; 31.5Gy in 3
fractions or 26Gy in 2 fractions [12].
In Erasmus MC - Cancer Institute the schedule of 38Gy in 4 fractions is used. It consists of a single
implant followed by four factions of 9.5Gy delivered twice daily with a minimum of 6h apart.
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1.3.4 Patient Selection for HDR BT in ErasmusMC
Patients diagnosed with low- and intermediate risk prostate cancer (PCa) can be treated with this
technique. Low-risk patients are dened as patients with clinical stage T1c-T2a, GS 6 and PSA ≤ 10 ng/ml,
whereas patients with PSA ≥ 10 ng/ml, T2b and/or GS 7, are dened as intermediate-risk PCa [13]. e
general requirements are shown below:
• Patients with clinical stage II (T1b-T2b) disease;
• Gleason score ≤ 7;
• Pre-treatment PSA ≤ 16 ng/ml;
• IPSS score before treatment ≤ 18/35;
• Prostate Volume before treatment ≤ 50 cm3(cc).
is criteria selection could vary between Institution/Hospital, these are the values used for my group
of patients reported in the paper of Alumini et al. [13].
It’s important to explain the meaning of the clinical stage II and the acronyms T1b-T2b. e next table
and gure explain the clinical stage according to UICC TNM Classication of Prostate Tumours (2009). e
entire classication of Prostate tumours is in Appendix A.
Table 1.1: Classication of Tumour Stage
T1b Tumour incidental histological nding in more than 5% of tissue resected
T1c Tumour identied by needle biopsy (e.g., because of elevated PSA)
T2a Tumour conned within Prostate and involve one half of one lobe or less
T2b Tumour conned within Prostate and involves more than one half of one lobe
Figure 1.5: Tumour stage classication according to TMN criteria. Taken from [14].
Another important parameter that should be taken into account is the Gleason score. A system of
grading prostate cancer tissue based on how it looks under a microscope. Gleason scores range from 2 to 10
and indicate how likely it is that a tumour will spread. A low Gleason score means the cancer tissue is similar
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to normal prostate tissue and the tumour is less likely to spread; a high Gleason score means the cancer tissue
is very dierent from normal and the tumour is more likely to spread.
e IPSS score is the International Prostate Symptom Score and it is used to evaluate the urinary
function before and aer treatment by questionnaires.
e last requirement is that the prostate size should be small, less than 50 cc. e reason for these con-
straints is: if the prostate gland is too large, the pelvic bones can shield the lateral parts of prostate gland. As
you can see in gure 1.6, if the prostate gland is larger than 50 cc, there will be an inappropriate implantation
of the needles and consequently a unsuitable dose coverage [15].
Figure 1.6: Illustration showing how the pelvic bones can shield parts of larger prostate glands. Taken from [15].
1.3.5 Clinical Procedure of HDR BT in ErasmusMC
e implantation of the needles is made under spinal anaesthesia and transrectal ultrasound guidance
(TRUS). When the patient and TRUS probe are ready the implantation starts. e template is positioned at the
perineum of the patient and the rst step is the insertion of 4 markers, two more dorsal and two more caudal.
ese markers will be useful for displacement checks and, if necessary, correction of the needles between
treatments and also for organ delineation.
e second step is the prostate immobilization, this is done by implantation of two special needles
where the tip has a kind of anchor. Aer these two steps, the needle implantation starts (the physician
already chose the needle conguration and the number of needles based on US). Regarding the needles, rst
the metallic needles are implanted and then they are replaced by plastic needles. e physicians start with
central needles and go for more ventral and dorsal needles. Figure 1.7 shows the schematic representation of
this procedure.
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(a) Schematic HDR BT implantation. (b) Image of treatment delivery.
(c) Schematic conguration of needles. (d) Image of needles template xation.
Figure 1.7: Needles implantation and treatment application. Taken from [16, 17, 18].
Following the implantation of the needles, the doctor checks whether the needles are close enough to
the bladder neck to obtain a good prostate coverage because there is a small part in the end of the needle that
the source can’t drive through. is evaluation is done by Cystoscopy1.
Aer this, a CT-scan is made. e images are imported in the treatment planning system where the
physicians do the organ/target delineation and the technicians do the needle reconstruction. e next step is
the dose distribution calculation. For more conformed dose distributions they use inverse planning. In inverse
planning, you take into account all constraints, and you mathematically determine the optimum parameter
values to provide the ideal answer.
In this way, the optimal dose distribution is obtained. Aer this step, the treatment is performed
respecting the treatment protocol that was mentioned in subsection 1.3.3.
1.3.6 Side eects of Brachytherapy
In the weeks aer brachytherapy treatment, normally, some secondary eects can occur due to treat-
ment. ese eects are divided to acute and late toxicities in 2 domains: Genitourinary (GU) or Gastroin-
testinal (GI) systems. e acute/early toxicities are dened as the symptoms occurring within 90 days aer
treatment and the late toxicities are classied as the complications occurring aer 90 days. e complete
classication can be seen in Appendix B.
e possible adverse events aer treatment for prostate cancer include: dysuria, urinary incontinence,
1Diagnostic procedure that is used to look at the bladder, collect urine samples, and examine the prostate gland. Performed with
an optic instrument known as a cystoscope, this instrument uses a lighted tip for guidance to aid in diagnosing urinary tract disease
and prostate disease.
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urinary retention, frequent voiding, hematuria, erectile impotence, diarrhoea, rectal pain and rectal bleeding.
e European Organization for Research and Treatment of Cancer (EORTC) and Radiation erapy
Oncology Group (RTOG) have a toxicity score based on questionnaires which have been used to assess the
toxicities that I mentioned before. e patient has been followed during the months aer treatment.
Urinary Retention
Urinary retention can be dened as the inability to spontaneously empty the bladder. For that reason,
the patients have an indwelling catheter in their bladder. is catheter drains the urine from the bladder into a
bag outside their body (see gure 1.8). According to the time when the symptoms start, the urinary retention
will be classied as acute or late urinary retention. In HDR BT, acute urinary retention (AUR) is most common
than late urinary retention.
Figure 1.8: Schematic representation of indwelling bladder catheter. Taken from [19, 20].
Rectal Bleeding
Rectal bleeding refers to the passage of bright blood via rectum. e rectum is the nal 15 cm of the
colon (large intestine) where faeces accumulate before being expelled from the body via the anal canal. Rectal
bleeding can be due to bleeding from anywhere in the lower gastrointestinal tract namely the colon, rectum
or anus. As well as in urinary retention, this side eect can be classied as acute or late complication. e
rectal bleeding associated to HDR BT is usually a late eect and depending on the severity, the patients could
use pads/diaper or not.
Chapter 2
Statistical Approach
In the most scientic areas, we want to know what the relation is between two categorical variables
and/or between continuous and categorical variables. First of all, the types of data need to be explained.
Categorical data/parameters is usually dened as an independent or predicting variable that contains values
indicating membership to one of several possible categories and it can be further categorized as either nominal,
ordinal or dichotomous.
• Nominal variables: parameters that have two or more categories, but which do not have an intrinsic
order, e.g. marital status (married, single, divorced, widowed);
• Dichotomous variables: nominal variables which have only two categories or levels and those are oen
assigned numerical values used as labels, e.g 0 = male 1 = female.
• Ordinal variables: variables that have two or more categories just like nominal variables only the cate-
gories can also be ordered or ranked. One example of that is when the answer of one question is: yes,
very much; yes, quite; yes, a bit; no, not at all.
Continuous variables are not restricted to particular values, e.g. reaction time, age, weight, height, etc.
Sometimes continuous data can be transformed in into categorical data, e.g. length < x vs ≥ x. is chapter
will provide a summarized view of the statistical approaches [based on [21, 22]], particularly, tests used for
categorical and continuous variables and their assumptions.
2.1 Statistical tests
2.1.1 Chi-Square
Chi-square test (χ2) is one of most used test to evaluate the association between two categorical vari-
ables. is statistical approach is based on the simple idea of comparing the frequencies observed in certain
categories to the frequencies you might expect to achieve in those categories by chance. e chi-square test is
always testing what is called the null hypothesis, which states that there is no signicant dierence between
the expected and observed result. e value of this test is calculated according to the following equation:
χ2 = Σ (fo−fe)
2
fe
(Eq.2.1)
Where, fo is the frequency of the observed data and fe is the frequency of the expected values. In this
specic research chi-square test of independence will be used with the following hypotheses:
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H0: e two categorical variables are independent.
Vs.
H1: e two categorical variables are related.
Associated to χ2 statistic value is the p-value or its signicance value. If the signicance value is small
enough, usually p-value≤ 0.05, the null hypothesis will be rejected and condence is gained in the hypothesis
that the two parameters are in some way related. is test has an important assumption related to expected
frequencies. Expected counts are the projected frequencies in each cell if the null hypothesis is true. In large
tables, the rule is that all expected counts should be greater than 1 and no more than 20% of expected counts
should be less than 5. If this assumption is broken, the result is a huge reduction in test power. When looking
at association between only two categorical variables, the solution for this problem is to use the Fisher’s Exact
test. If there are more than 2 categorical variables, there are other tests that can be used. However, that is
beyond the scope of this sections.
2.1.2 T-student test and Mann-Whitney U-test
To analyse relations between continuous parameters, the t-student test can be used. e t-student test
evaluates mean dierences in variables of interest between two groups. e assumptions are:
1. e data is continuous;
2. e data follow the normal probability distribution;
3. e variances of two populations are equal;
4. e two samples are independent. ere is no relationship between the individuals in one sample as
compared to the other.
If the normal distribution is not met, the correspondent non-parametric test of t-student called Mann-
Whitney U-test can be used. erefore, one of the rst steps before applying the statistical test is to evaluate
the distribution of the data. To assess the normality the Kolmogorov-Smirnov test is performed. If the signi-
cance value of that test is lower than 0.05, we will conclude that there is a deviation from normality. erefore,
when the data breaks assumption 2 and the variance of two populations is unknown, the suitable test for this
cases is the Mann-Whitney test.
e Mann-Whitney test uses the ranks of the values rather than the values themselves, so this test
compares the median dierences between two dierent groups. e statistic value of this test is calculated
by:
U = n1n2 +
n1(n1+1)
2 −R1 (Eq.2.2)
Where, n1 and n2 are the sample sizes of group 1 and 2 respectively, and R1 is the sum of ranks for
group 1. erefore, the hypotheses in this test are:
H0: e median of certain variables is the same across the categories.
Vs.
H1: e median of certain variables is not the same across the categories.
Once again, when the signicance value is lower than or equal to 0.05, the null hypothesis is rejected.
erefore, in that case, we can conclude that those variables have dierences across the groups and because
of that we gain condence that there is in some way an association.
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2.2 Logistic Regression
e linear logistic regression is commonly used for epidemiology, but it can also be used for other areas
of medicine as, for instance, radiotherapy. is type of statistical approach is computed in order to describe
the relationship between disease/toxicities and one or more explanatory variables which might inuence the
dependent variable. Logistic regression has some important features. One of them is that the dependent
variable must be dichotomous, which means it should have values as 0 or 1, depending on disease status (e.g.
alive or dead, case or control).
Another important characteristic is the output of this method. While linear regression predicts the
value of dependent variable from one or more predictor variable, logistic regression can predict the probability
of Y occurring given known value(s) of X. e logistic regression equation is:
P (Y ) =
1
1 + e−(b0+b1X1+b2X2+...+bnXn)
(Eq.2.3)
Where b0, b1,. . ., bn are the coecient values estimation. In equation 2.3, you might notice that the
equation within e (the base of natural logarithms) brackets is similar to the simple linear regression. e
independent variables in logistic regression may be continuous or discrete, qualitative or quantitative. e
output of the analysis provides important parameters such as the coecient values estimation (b0, b1,…, bn),
the p-value, the odds ratio and 95% Condence Interval. e coecient value for each X variable is estimated
using a technique called maximum-likelihood estimation. is method chooses the coecients that make the
observed values most likely to have occurred.
e p-value is a function of the observed sample results that is used for testing the statistical hypothesis
as previously described. If the p-value is less than or equal to the chosen signicance level (1% or 5%), the test
suggests the Y variable is beer explained when X1, X2,…, Xn are added than when only the intercept (b0) is
used. Usually, using only b0 is the null hypothesis.
In the logistic regression, the statistical test used is the Wald Test and the associated z-statistic is
calculated by:
z = bSEb (Eq.2.4)
Where b is the regression coecient and SEb is the standard error associated to the regression coef-
cient.
Another important parameter is the odds ratio, which is essential for a good interpretation of logis-
tic regression. e odds ratio (OR) is a tool to quantify how strongly the presence or absence of a certain
characteristic is associated with dependent variable Y. Even so, the OR is an indicator of the change in odds
resulting from a unit change in the predictor. e OR of a certain feature is given by an exponential of this
property (e.g. exp(b1)) and it can be interpreted as:
• OR > 1: if predictor increases, chance of Y increases;
• OR < 1: if predictor increases, chance of Y decreases;
• OR = 1: predictor does not aect chance of Y.
e condence interval (CI) for odds ratio is another way to analyse the association between predictors
and dependent variable. e basic idea is to construct a range of values within which it is expected that the
population value falls. In particular, the CI provides the likelihood that it contains the true value of the issue
we are trying to estimate. If the entire interval is above 1, we conclude a positive association, while an interval
below 1 indicates negative association between the dependent variable and predictors. In other words, if the
interval contains 1, we cannot conclude there is an association.
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2.2.1 Univariate and Multivariate Method
Univariate analysis is the simplest form of statistical analysis. is method assumes that the response
variable is inuenced only by one factor/predictor. In other words, there is one dependent variable and one
independent variable. e univariate linear logistic regression equation is given by:
P (Y ) =
1
1 + e−(b0+b1X1)
(Eq.2.5)
Multivariate analysis assumes that the dependent variable could be explained by more than one in-
dependent variable. In other words, the response variable is inuenced by multiple factors. In this case, the
model equation is given by Eq.2.3.
Usually, the univariate method is used for pre-selection of predictors to include in multivariate
analysis. In this method, we do not only include the parameters with p-value ≤ 0.05 but we can use an
less conservative aitude and accept parameters with p-value ≤ 0.2 or 0.3.
is strategy has advantages such as reducing problems of overing and stepwise selection. e
predictors are eliminated at an early stage if they do not meet the univariate pre-selection threshold. e
univariate method is prey useful with large data sets because it reduces the number of predictors and, con-
sequently, the complexity of the model.
In case of a small dataset with few cases versus controls, the logistic regression only allows to build
a model with 1 covariate per 10 cases [24, 25]. In these cases, the multivariate analysis can be used to assess
whether the variable of interest is aected by another variables or not. In other words, other parameters are
added as confounders in the analysis of the variable of interest. erefore, in order to assess if those para-
meters are confounding factors, adjusted OR and unadjusted OR can be compared. Basically, when adjusted
OR changes substantially from unadjusted OR, we conclude that those confounder parameters aected the
outcome and the variable is not an independent factor associated with the dependent variable.
2.3 Missing Values
In data analysis, one of the most common problems is missing values. is oen occurs when the data
is dependent upon responses to questionnaires, old data or medical les. ere are dierent types of missing
values and the way to deal with them can also be dierent. Missing values can be dened as, missing values
completely at random (MCAR) or missing values at random (MAR). A database with missing values is MCAR
if the subjects who have missing data are a random subset of the complete sample of subjects. In order words,
imagine your data set as a large matrix in which the missing values do not follow a specic paern. e
typical example is when a questionnaire of a study subject is accidentally lost.
e data is classied as MAR when the missing values are associated with a certain patient fea-
ture/behaviour at the time of analysis. One example of this is when you want to assess a certain symptom
score aer treatment: if the patient is not feeling well, he is more likely to not answer the questionnaire.
ere are several methods to minimize this problem, from traditional approaches until more modern
techniques. Examples of traditional techniques are listwise/pairwise deletion or mean/median substitution.
ese techniques are the most simple and less time consuming, but could result in biased outcomes and it
may reduce or increase the statistical power.
Listwise/Pairwise Deletion
Listwise or casewise deletion is the default option in most statistical soware. e listwise deletion
works this way: whenever the statistical soware nds one missing value in one variable, it deletes all va-
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riables for that subject. is technique is oen used, but it results in 20%-50% loss of the data and it could be
a problem when using a small population.
Pairwise deletion uses all available information. e procedure cannot include a particular variable
when it has a missing value, but it can still use the case when analysing other variables with non-missing
values.
Mean/Median Substitution
Another traditional approach to work with missing values, probably the most simple one, is the mean
or median substitution. e mean imputation consists of replacing the missing values of a certain variable by
the mean of all known values for that variable. is procedure is used when the variable with missing values
is normally distributed. When the distribution of the parameter with missing values is skewed the median
should be used rather than mean.
Some other variant of this method is the mean/median substitution for subgroups. In case of a variable
with missing values divided by group, the median for each group can be calculated to replace the missing
values of the correspondent group. is procedure results in a beer estimate and preserves more variance
than giving everyone with a missing value the overall median [26].
Single and Multiple Imputation
Several newer techniques have been developed for dealing with missing values and two new ap-
proaches will ne discussed here: Single Imputation using Expectation Maximization (EM) and Multiple Im-
putation. Both techniques can only be applied when the missing values are classied as MCAR.
Single imputation using EM creates a new data set that has no missing values. is method is based
on the observed relationship among the variables and replaces the missing values by the maximum likelihood
value.
Multiple imputation estimates the missing values using n iterations instead of only one. In SPSS tool
this method has three options:
1. Markov chain Monte Carlo (MCMC) method: suitable for data with an arbitrary paern of missing
values. e method ts a univariate (single dependent variable) model using all other available variables
in the model as predictors, then imputes missing values for the variable being t. e method continues
until the maximum number of iterations is reached, and the imputed values at the maximum iteration
are saved to the imputed dataset.
2. Monotone method: noniterative method that can be used only when the data have a monotone paern
of missing values. A monotone paern exists when you can order the variables such that, if a variable
has a nonmissing value, all preceding variables also have nonmissing values. Here, the method to
impute is equal to MCMC procedure only the univariate model is dierent.
3. Automatic method: SPSS chooses an imputation method based on scan of your data and uses the
monotone method if the data show a monotone paern of missing values; otherwise, MCMC is used. If
you are certain of which method you want to use, you can specify it in SPSS soware.
Aer imputation all statistical tests and logistic regression can be applied. Figure 2.1 illustrates the
multiple imputation method.
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Figure 2.1: Illustration of the method of multiple imputation. Each box represents a data value where the columns are
variables and the rows are individuals. Blank spaces represent the missing values. βi is the estimate of interest from the
completed dataset number i, βMI is the estimate obtained from multiple imputation and m is the number of iterations.
Taken from [27].
2.4 Receiver operating characteristic curve - ROC curve
e receiver operating characteristic (ROC) curve [28, 29], which is dened as a plot of the test sen-
sitivity as the y coordinate versus its 1-specicity or false positive rate (FPR) as the x coordinate. It is an
eective method of evaluating the quality or performance of diagnostic tests, and is widely used in medicine
to evaluate the performance of many diagnostic tests. Basically, the ROC curve allows quantication of how
accurate medical diagnostic tests (or systems) can discriminate between two patient states, typically referred
to as ”diseased” and ”nondiseased”.
Sensitivity and specicity, which are dened as the number of true positive decisions (the number of
actually positive cases) and the number of true negative decisions (the number of actually negative cases),
respectively, constitute the basic measures of performance of diagnostic tests (see table 2.1).
Table 2.1: Decision Matrix.
Diagnostic test results Disease statusPresent Absent
Positive a (TP) b (FP)
Negative c (FN) d (TN)
Total n1 = a+c n2=b+c
Note:
TPR = True positive rate (sensitivity)= TP/(TP+FN);
FNR = False negative rate (1-sensitivity)= FN/(TP+FN);
TNR = True negative rate (specicity) = TN/(TN+FP);
FPR = False positive rate (1-specicity) = FP/(TN+FP);
n1=patient with disease; n2=patients without disease.
Several summary indices are associated with the ROC curve. One of the most popular measures is the
area under the ROC curve (AUC). AUC is a combined measure of sensitivity and specicity. It is a measure
of the overall performance of a diagnostic test and is interpreted as the average value of sensitivity for all
possible values of specicity.
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e accuracy of the test is evaluated according to the following scale:
• AUC = 0.9-1: Excellent test accuracy;
• AUC = 0.7-0.9: Good test accuracy;
• AUC = 0.6-0.7: Moderate test accuracy but it is beer than relying on pure chance;
• AUC = 0.5-0.6: If AUC is close to 0.5, it relies on pure chance to distinguish those subjects with versus
those without a particular disease, the resulting ROC curve would fall along this diagonal line, which
is referred to as the chance diagonal.
In summary, the ROC curves as close as possible to the superior le corner of the ROC plot are the
most optimal. Figure 2.2 depicts three dierent ROC curves. Considering the area under the curve, test A is
beer than both B and C, and the curve is closer to the perfect discrimination. Test B has good validity and
test C has moderate.
Figure 2.2: Comparision between ROC curves. Taken from [29].
2.4.1 Optimal cut-o values
ROC curve analysis has several advantages. First, AUC is not aected by decision criterion and it is
also independent of prevalence of disease since it based on sensitivity and specicity. Second, we can easily
obtain the sensitivity at a specic FPF by visualizing the curve. Another advantage and one of the most
important tools of ROC is the possibility to determine the cut-o value for a certain parameter.
ere are two methods to determine the optimal cut-o values. e rst method gives equal weight to
sensitivity and specicity with no ethical, cost and prevalence constraints. e second method gives dierent
weight to sensitivity and specicity. For example, given a disease with low prevalence and high cost of false
positive diagnosis, the cut-o point may be chosen at higher value to maximize the specicity.
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3.1 Introduction
Prostate cancer (PCa) is the second cause of death in men, the rst one is the lung tumours. is is more
frequent in older men (≥ 50 years old). In Portugal, it is estimated that prostate cancer has an incidence of
108 cases per 100 000 inhabitants (in 2009) and the mortality rate is approximately 36 per 100 000 inhabitants
(in 2012) [30]. It represents approximately 3.5% of all deaths and more than 10% of other types of cancer
deaths [31]. In the Netherlands, 11 158 new cases of prostate cancer are diagnosed each year, and one out
of 35 patients will die from prostate cancer [32] and expected to increase due to growth and ageing of the
population. is kind of tumour can be treated by several techniques, for instance, radical prostatectomy,
chemotherapy, External Beam Radiotherapy (EBRT), Intensity Modelated Radiotherapy (IMRT), Hormone
erapy and Brachytherapy (BT). In the last years, the most used technique is EBRT or IMRT. A new technique
appeared in early twentieth century called Brachytherapy. is technique inserts the sources within the
patients, so is only available for certain types of tumours as prostate tumours, gynaecology tumours and
other supercial or interstitial tumours.
e rst treatment that was used to treat prostate cancer was called Low-dose-rate Brachytherapy
because they used low-dose rate sources (e.g. 125I).ey implanted seeds permanently in the prostate volume
to achieve the desired dose distribution. Over a period of months, the level of radiation emied by the seed
sources will decline to almost zero. is technique continues to be used currently, but not with the same force.
ere is an other type of BT called HDR, its uses high-dose rate sources. In the beginning, this tech-
nique had a big problem because of the radiation exposure to operators from the manual application of the
radioactive sources. So, the huge growth only occurred in 1950s and 1960s with the development of remote
aerloading machines. With this development the treatment can be delivered with no radiation exposure to
the operators.
3.2 HDR BT for PCa
In the paper of Kova´cs et al. [11] several advantages of remote temporary aerloading brachytherapy
are illustrated as:
• Accurate positioning of the source by rst implanting non-active guide needles;
• Possibility to choose the source positions over the length of the needle;
• No target movement during radiation;
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• Stepping source technology allowing for dose and volume adaptation due to adjustment of source dwell
locations and times according to 3D imaging based individual dose prescription before irradiation.
Introducing a remote aerloading technique combined with the technological developments in 3D
imaging, such as transrectal ultrasound (TRUS), as well as treatment planning soware developments resulted
in an appropriate target delineation and guidance of the needles.
Aer these technical developments, HDR brachytherapy started to be used in combination with con-
ventional EBRT. In this way, the GEC/ESTRO recommendation had to be updated for HDR aerloading
brachytherapy for localised prostate cancer in 2013 [12]. In this paper, they enumerated several advantages
of this technique as:
• e use of image guided needle placement enables accurate implantation which can be extended to
include extracapsular disease and seminal vesicles.
• It is possible to individualise the source positions over the full length of the prostate based on a dened
planning target volume and organs at risk. Dose distribution optimization by inverse planning enables
highly conformal dose delivery.
• e xation of the prostate by the implant and rapid radiation delivery minimises the problems of target
and OAR movement.
• e use of high dose per fraction has a biological dose advantages for tumours with a low α/β ratio of
which prostate is a common example.
• e use of a singles source for all patients using a multipurpose facility makes HDR BT highly cost
eective.
ey also described some disadvantages as the use of fractionated schedule which results in more
work load per patient. is paper is a important tool for HDR BT for prostate cancer because they show
all requirements regarding to patient selection, organ delineation, implant procedure, planning aim and dose
prescription and how the treatment should be delivered. So, this is the most recent guide for HDR BT for
prostate cancer.
3.3 Results HDR BT for PCa
When we use these techniques to treat the patient, the main objective is to treat the prostate while
protecting the organs at risk and the normal surrounding tissue. In this way, it is important to evaluate the
toxicity in these organs due to this kind of treatment.
In 2008, the group of Ishiyama et al. [33] from Japan, sought to evaluate the severity of genitourinary
(GU) toxicity HDR brachytherapy combined with hypofractionated external beam radiotherapy (EBRT) and
they also looked for factors that might aect the severity of GU toxicity. ey evaluated 100 Japanese patients
and they observed that their patients have a high value of GU toxicity (a signicant percentage 28% ). Aer
they applied the multiple logistic regression model, they found that the volume of the prostatic urethra is
associated with the grade of acute GU toxicity and that urethral dose is associated with the grade of late GU
toxicity.
Another group, Aluwini et al. [34] from e Netherlands in 2011, reported the clinical outcomes
and early and late complications in patients with low- and intermediate- risk of prostate cancer who were
treated with a combined technique (EBRT + HDR BT). ey follow-up the patients treated between 2000 and
2007 and they show that the treatment with interstitial HDR BT + EBRT resulted in a low incidence of late
complications and a favourable oncology outcome aer 7 years follow-up. In this research group, the freedom
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of biochemical failure was 97% and failure-free survival 1 was 96%. ey found excellent results for low- and
intermediate risk PCa patients using EBRT plus HDR BT and they suggested the use of less intensive treatment
for this group, using monotherapy HDR BT. ey also proposed that EBRT plus HDR BT should be used for
high-risk prostate cancer.
Recently, Aluwini et al. [13] published another study where they reported their results on toxicity
and quality of life aer HDR BT monotherapy. ree months aer treatment, acute GU and GI toxicities
were reported in 10.8% and 7.2%. Late grade ≥ 2 GU and GI toxicity were reported in 19.7% and 3.3% of
patients 12 months aer HDR BT. ey also observed a biochemical failure rate as 2.4% and the cancer-specic
survival was 100%. An interesting result that they also found was that 8 patients needed an indwelling bladder
catheter due to acute urinary retention. In this way, this group decided to change the criteria for patient
selection regarding to IPSS score. Nowadays, in clinical practice in Erasmus MC - Cancer Institute (Roerdam,
Netherlands) only patients with IPSS ≤ 18/35 are selected for HDR BT as monotherapy . e last important
result is regarding the erectile function aer treatment. eir patients recovered almost to normal erectile
function aer 60 months of treatment as you can see in gure 3.1.
Figure 3.1: Sexual Functioning score vs Time of Evaluation in months. Taken from [13].
So they concluded that HDR BT shows a good clinical outcome and acceptable acute and late toxicity.
Even so, these types of toxicities still appear in a considerable amount of patients. erefore,it is important
to evaluate whether dosimetric values predict the occurrence of GI and/or GU toxicities.
In Berlin, Ghadjar et al. [35] published a study in 2009: their main goal was to evaluate the acute and
late GU and GI toxicity aer HDR BT as monotherapy for for low- and intermediate PCa patients. ey found
some association of late grade 3 GU toxicity with urethral V120 and V100 and also with D902 of PTV. So,
they concluded that reduction of the irradiated urethral volume may reduce the GU toxicity and potentially
improve the therapeutic ratio of this treatment. Six years later, the some group published a similar study where
they used the same group of patients. Ghadjar et al. [36], in this current study, used other kind of statistical
analysis (multivariate Cox regression) to nd within a huge amount of DVH parameters which parameters
are associated to grade 3 GU toxicity. Regarding the urethral V120 they found the same association but also
found that GI toxicity was negligible and that erectile function preservation rate was excellent as Aluwini at
el. [13] found recently.
erefore, the main issue in this area is the urethral strictures, urinary retention and rectum toxicities
due to HDR BT. A signicant proportion of patients still have some acute and late toxicities associated to the
GU system. Nowadays, an important research area is related to this problem, where the researcher try to nd
some correlation between DVH parameters and these kind of toxicities. In this way, in 2009, Konishi et al.
[37], published a study where the main goal was to evaluate the correlation between dosimetric parameters
and late rectal and urinary toxicities. ey use 83 patients from Japan treated from 2001 through 2005. e
1Failure-free Survival: is dened as a percentage of patients still alive without evidence of biochemical or clinical failure
2D90: the dose that covers 90% of the target volume
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total prescribed dose was 54Gy in 9 fraction over 5 days. ey found some dosimetric parameters for rectum
signicantly high in 18 patients who presented with late rectal toxicities. Regarding to the urethral toxicities
they did not nd any correlation. e next tables in gure 3.2 show the main results of this paper.
(a) Comparison of mean values of rectal dosimetric
parameters.
(b) Comparison of mean values of urinary dosimetric
parameters.
Figure 3.2: Rectal and Urethral Dosimetric Parameters Evaluation. Taken from [37].
e statistical most signicant dierence was observed for V40 and D5cc3 for rectum. In this way,
they suggested that rectal V40 ≤ 8cc and D5cc ≤ 27Gy may be dose-volume constraints in HDR BT.
Recently, in 2014, a research group from UK, Diez et al. [38], tried also to evaluate and nd some
correlation between dosimetric parameters related to urethral strictures and dose schedule. ey evaluated
4 dierent dose schedules and 213 patients. In these patients 10 urethral strictures were identied. For eva-
luation, they divided the urethra in prostatic urethra and membranous urethra . e rst volume was further
divided in 3 equal parts and the membranous urethra was dened from apex of prostate to the bulb of penis
measuring approximately 1.2cm in length. ey do this for checking whether some part of urethra is more
sensitive to dose. As dosimetric parameters they use only six parameters as V10Gy (%)4, V8.5Gy (%), D30 (Gy),
D10 (Gy), Dmax (Gy) and Dmean (Gy). As results of their study, they did not nd any dierence between
stricture cases and control cases (people without urethral strictures) in terms of dosimetric parameters.
e factors that predict which patients have a greater chance of developing acute urinary retention
(AUR) are not very well known, mainly for HDR BT. In literature, there are several LDR BT studies reporting
possible risk factors of AUR, mainly, related to clinical parameters. Bucci et al. [39], reported IPSS as impor-
tant predictor of AUR. Roelozen et al. [40] and Mabjeesh et al. [41] , found IPSS and prostate volume
before treatment as predictors of AUR. While, Lee et al. [42] reported number of needles and prostate volume
aer treatment as variables associated to AUR. More authors have reported prostate volume [43, 44] as an
associated factor with AUR.
In 2010, Roelozen et al. [45] looked to assess the inuence of dose in dierent prostate regions, and
3D5cc: e dose delivered to the 5 cubic centimeter volume.
4V10Gy: Percentage of volume that receive 10Gy
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the inuence of anatomic variation on the risk of acute urinary retention aer 125I prostate brachytherapy.
ey used 100 patients, 50 as considered as cases (with AUR) and other 50 as controls (without AUR). e
dosimetric parameters analysed were D10, D50, D90, V100 5 and V200 and they used the logistic regression
analysis. e group found that AUR is associated with high dose in bladder neck mainly, they reported mean
bladder neck D90 = 65Gy in cases versus 56Gy in controls (p=0.016), and mean bladder neck D10 = 128Gy
vs. 107Gy in controls (p = 0.018).With this study, they also re-emphasized the need to avoid the insertion of
needles and seeds into the bladder neck, in order to reduce the risk of AUR.
Most recently, in 2014, a research group from the Department of Radiation Oncology and Medical
Physics in New York, Hathout et al. [46], reported that the dose to the bladder neck is the most important
predictor for Acute and Late Toxicity aer LDR BT. ey evaluated 927 patients treated between 2002 and
2013. e clinical and dosimetric factors were evaluated with Cox regression, ROC curve and univariate
and multivariate method. is group found that the bladder neck D2cc ≥ 50% is the strongest predictor for
grade ≥ 2 acute and late urinary toxicities, so they suggested to include bladder neck constraints into the
brachytherapy planning to decrease urinary toxicity (see gure 3.3).
Figure 3.3: Results of Univariate and Multivariate analysis. Taken from [46].
Another possible side eect of HDR BT is rectal bleeding. e factors that predict rectal bleeding
are not very well known for HDR brachytherapy as monotherapy treatment but there are several studies
reporting those aer EBRT or LDRBT. In 2004, Akimoto et al. [47] investigated the incidence and severity
of rectal bleeding aer high-dose hypofractionated radiotherapy. ey used a data set of 52 patients where
13 patients developed grade 2 or worse rectal bleeding. ey evaluated clinical and dosimetric parameters by
using univariate and multivariate analysis. On univariate method, they found diabetes mellitus (p < 0.001)
and rectum V30 ≥ 60%, V50 ≥ 40% (p < 0.05), V80 ≥ 25% and V90 ≥ 15% (p < 0.001) as a signicant risk
factors for the occurrence of grade 2 or worse rectal bleeding. Only history of diabetes mellitus retained the
signicance value on multivariate method as the most important factor. Herold et al. [48] reported also
diabetes as a signicant risk of the development of late grade 2 GI and GU complications aer EBRT.
In 1998, Hu et al. [49] did not nd obvious dierence in rectal wall radiation for patients who did or
not experience resolution of their bleeding. In 2001, Jackson et al. [50], reported a signicant correlation
between grade 2-3 rectal bleeding and “intermediate doses” (around 40-50Gy) in a randomly chosen sample of
patients treated with 70.2-75.6Gy conformal radiotherapy. ey suggested large fractions of rectum receiving
those doses may result in a loss of repair capacity of the mucosa cells, which may lead to bleeding. Later
5V100: Percentage of volume that receive at least 100% of prescribed dose.
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on, one research group from Italy (Fiorino et al. [51]), found V50Gy > 60-65% and V60Gy > 50-55% as
statistically signicant variables associated to rectal bleeding aer EBRT treatment. Another research group
from Italy, Cozzarini et al. [52], reported that late rectal bleeding is associated with doses between 66.6-
70.2Gy by using EBRT as treatment technique. Few investigations found a possible relationship between
rectal volume and bleeding, [51, 53, 54], particularly, there are one inverse correlation between the rectum
dimension and the fraction of that included in the high-dose region.
Regarding to LDRBT studies reporting some factors associated to this side eect, in 2004, Sherertz et
al. [55] evaluated the contribution of various clinical and radiation treatment parameters to the likelihood
of late rectal bleeding aer LDR BT. ey used univariate method and they found V100, V200 and V300 as
statistically related to rectal bleeding. Later on, in 2007, Ohashi et al. [56] from Tokyo Medical Center, Japan,
aer multivariate analysis reported maximal rectal dose (p < 0.001) as the only signicant factor associated
to RB. Recently, in 2012, Harada et al. [57] from Japan, investigated the association between some clini-
cal and dosimetric parameters and RB aer LDR BT by using the data set of 24 patients with RB versus 65
without. ey found as the most important factor the usage of anticoagulants (p = 0.007). erefore, there
are several LDR BT studies reporting some factor associated to this side eect and few studies reported this
problem using HDR BT even combined with other types of brachytherapy. In 2006, one research group from
department of radiation oncology from Japan explored the incidence of grade 2 or worse rectal bleeding aer
HDR brachytherapy combined with hypofractionated EBRT. Univariate analysis was performed to evaluated
dosimetric parameters, such as rectal V10, V30, V50, V80, and some clinical variables as prostate volume,
number of needles and patient age. is group, Akimoto et al. [58], found dierences in the percentages of
the entire rectal volume receiving 10%, 30% and 50% between those with and without bleeding.
Recently, in 2012, Okamoto et al. [59], evaluated the predictive risk factors for grade 2 or worse rectal
bleeding aer HDR BT combined with EBRT in 216 patients. ey estimated the radiation doses delivered
by HDR BT alone to 5% and 10% of rectum in patients with RB as 5.1Gy and 4.1Gy, respectively, and those
results demonstrated that high dose areas, even if they include only small volume, should be carefully taken
into consideration during HDR BT treatment planning suggesting V5 and V10 as risk factors for late rectal
bleeding.
In conclusion, HDR and LDR BT are the most important technique for prostate cancer but still have
some secondary problems related to dose delivery at OAR. is is the reason for many research groups to try
to nd some explanation or some new constraints in dose planning in order to improve the quality of life of
the patients aer the treatment.
Chapter 4
Predictive factors for acute urinary
retention aer HDR BT as monotherapy
for low risk prostate cancer
4.1 Purpose
To evaluate clinical and dosimetric parameters related to acute urinary retention (AUR) needing a
temporary bladder catheter (CAD) aer high-dose rate brachytherapy as monotherapy treatment for prostate
cancer.
4.2 Materials and Methods
In this study, patients with histological conrmed prostate carcinoma (PCa), clinical stage T1b-T2b,
Nx-0, Mx-0, Gleason score≤7, PSA≤ 16 ng/ml and WHO performance 1status 0-2 were treated with HDR BT
monotherapy. HDR BT monotherapy was administered in four fractions of 9.5Gy with a minimum interval
of six hours within 36 hours using one implant.
Predictive factors for AUR were investigated in 2 dierent groups, i.e., small group and large group. In
the small group, the number of patients in evaluation was reduced because clinical and dosimetric data were
selected and evaluated in more detail, e.g., we analysed dose in dierent regions of urethra. In the large group,
we analysed data from HDR BT database for PCa of ErasmusMC - Cancer Institute. e following sections will
explain the main dierences between the small and the large group in detail.
4.2.1 Patients
Data set of 42 subjects - Small Group
e the small group is a selection from patients treated between 2007 and 2015 (210 patients). Fourteen
of 210 (6.7%) patients received a CAD because of AUR aer primary treatment for their PCa with HDR BT.
ese were analysed together with 28 other patients with grade ≤ 1 GU and GI toxicities 2. Table 4.1 shows
the patients and treatment characteristics.
1WHO performance status in Appendix C
2GU and GI classication in Appendix B
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Data set of 210 subjects - Large Group
e large group consists of 210 patients treated between 2007 and March 2015. e treatment scheme
and the number of cases with AUR aer treatment are the same as it was mentioned before. ese 14 patients
who needed CAD were analysed together with all other 196 patients who did not receive a bladder catheter
aer treatment. Patients and treatment characteristics are shown in table 4.1.
Table 4.1: Patient, tumour and treatment characteristics. Small group = 14 CAD (2nd column)+ 28 no-CAD (3rd column);
Large group = 14 CAD (2nd column) + 196 no-CAD (4th column).
CAD no-CAD no-CAD*
Characteristic (n= 14 patients) (n= 28 patients) (n= 196 patients)
Patient and tumour
Age at implantation (y) 67.6 (57.8-74.7) 68.9 (53.2-79.3) 66.8 (44-79)
Clinical Tumour Stage
T1 (n (%)) 9 (64.3%) 16 (57.1%) 124 (63%)
T2 (n (%)) 5 (35.7%) 12 (42.9) 68 (35%)
Gleason sum-score
< 7 (n (%)) 12 (85.7%) 25 (89.3%) 137 (70%)
=7 (n (%)) 2 (14.3%) 3 (10.7%) 24 (12%)
iPSA (ng/ml) (mean (min-max)) 8.4 (4.5-12) 7.8 (3.8-14) 7.9 (1.4-16)
Pretreatment IPSS (mean (min-max)) 8 (2-19) 5 (0-16) 7 (0-24)
Baseline urinary ow (Qmax; ml/s)
(mean (min-max)) 12.4 (7-24.9) 16.2 (2-37) 16.1 (2-41.2)
Treatment
TRUS volume (cm3) (mean (min-max)) 38.5 (19.6-57.1) 32.5 (18.6-50) 33.5 (15-55)
Needles (mean (min-max)) 18 (14-23) 17 (13-23) 17 (12-23)
PTV volume (mean (min-max)) 67.1 (44.1-105.9) 49.1 (25.8-79.26) 55.7 (23.8-94.7)
Urethra length (mean (min-max)) 57.9 (45-69) 60.7 (39-123) 59.7 (33-123)
Abbreviations:
CAD = patients needed a temporary bladder catheter aer treatment;
iPSA = initial prostate-specic antigen level;
IPSS = international prostate symptom score; TRUS =transrectal ultrasound;
PTV = planning target volume at treatment;
* Data base is not complete: large amount of missing values.
4.2.2 Organs Delineation
Small Group
For all patients, organs at risk (bladder, urethra) were delineated. e urethra was divided into ure-
thra membranous and urethra prostatic. Urethra prostatic was the urethra part within the boundaries of the
prostate. e urethra prostatic was divided into superior, mid and inferior equals parts [38]. e membra-
nous urethra was dened as 2 cm of the urethra caudal to the prostate apex. e bladder neck was dened
as a bladder portion around the urethra opening adjacent to the prostate. Figure 4.1 illustrate the organs
delineations. On the sagital view the bladder is represented as a dark blue contour, bladder neck as a green
contour, prostate as a red contour, membranous urethra as a pink contour and prostatic urethra superior, mid
and inferior as blue, violet and orange, respectively.
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Large Group
In this group, bladder and urethra were not divided by dierent substructures and all delineations
were made by the physicians and technicians at the treatment day according to the treatment protocol.
Figure 4.1: e delineated organs in the planning CT scan and a schematic representation of dierent parts of bladder
and urethra. PUS = Prostatic Urethra Superior, PUM = Prostatic Urethra MID, PUI = Prostatic Urethra Inferior and UM
= Membranous Urethra.
4.2.3 DVH and Clinical Parameters Selection
Small Group
For all delineated structures, the following dosimetric parameters were calculated as presented in table
4.2. e DVH parameters were dened as:
• Dxcc: dose received by x cc of volume;
• Dx: dose received by x % of volume;
• Vx: % or cm3 (cc) of volume receiving x % of PD.
Aer the extraction from Treatment Planning System Oncentra by Elekta, only some of these param-
eters were used on univariate analysis and they are represented in table 4.2 in bold. Correlation table together
with medical opinion were used to select the parameters. Table 4.3 presents the selected clinical variables and
the summarized choices for cut-o points.
Table 4.2: List of DVH parameters
Organs DVH Parameters
Bladder D1cc, D2cc, D5cc, D25, D50, V75, V80, V90, V95, V100, V105, V110
Bladder Neck D0.1cc, D0.5cc, D1cc, D2cc, V80, V90, V100, V105, V110
Prostatic Urethra Superior/Mid/Inferior D0.1cc, D0.5cc, D1cc, D5, D10, D20, D30, V100, V105, V110, V120, V150
Membranous Urethra D0.1cc, D.05cc, D1cc, D2cc, D5, D10, D15, D20, D30, V100, V120, V150
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Table 4.3: List of cut-o values for clinical parameters.
Clinical Variables Cut-o Values
TRUS volume* 40 cc
Qmax* 10 or 15 ml/s
IPSS* 10
Urinary residue* 30 ml
Nr. needles 17
PTV volume 50 cc
Urethra length 50 mm
Age 70 years
*Baseline variables
Large Group
e selection of DVH parameters for this group is dierent. For the delineated structures, the following
dosimetric parameters were used: bladder D1cc, D2cc, bladder D10 and D25, urethra D1cc, urethra D1 and D5.
e selection of clinical variables equal to small group. ese parameters were extracted from ErasmusMC -
Cancer Institute HDR BT for PCa database.
4.2.4 Statistical Analysis and Missing values
SPSS (version 21) was used for statistical analysis of the data. In this phase, DVH parameters and
clinical variables have been selected to evaluate according to dierent methods.
On the rst method (Method A), multivariate logistic regression (MVA) analysis was performed in-
cluding all DVH parameters and clinical parameters with a threshold p-value of ≤ 0.2 on univariate logistic
regression. MVA was built using stepwise backward elimination method. is technique consists in including
all variables in the model. en, it analyses each variable individually and if that parameter does not meet the
criterion for inclusion, it is eliminated from the model. is procedure continues until all variables have been
considered for elimination. e nal model contains all of the independent variables that meet the inclusion
criteria. P-values ≤ 0.05 were considered statistically signicant on MVA.
On the second method (Method B), the association between AUR and independent dosimetric and
clinical parameters was assessed using Mann-Whitney test for DVH variables and Chi-square/Fisher’s ex-
act test for clinical ones. e parameters showing p-values < 0.05 or parameters showing p-value close
to assume statistical meaning and/or reported as important factor in previous studies were evaluated on
multivariate logistic regression adjusted by the following confounders: IPSS, Age, needles, PTV volume and
urinary residue. is approach is based on the method followed by Roelozen et al. [45].
Cross-validation using receiver operating characteristic (ROC) curve analysis was used to assess how
well the found parameters were predicting for AUR. e area under ROC curve (AUC) shows the capability
to distinguish no-AUR patients from AUR patients. Additionally, this method was used to conrm the cut-o
points investigated in this study. is approach is explained in detail in chapter 2 section 2.4.
Qmax missing values in the small group were replaced using dierent techniques as Median Substi-
tution, Single Imputation using EM and Multiple Imputation. e single imputation using EM and multiple
imputation are tools of SPSS. In large group, missing values were replaced by using multiple imputation
MCMC.
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4.2.5 Statistical Analysis Methodology
e rst step of this project was to apply Method A. erefore, several experiments were done called
“TESTA.”. ose were built according to the results from previous tests. With these tests, dierent techniques
to handle missing values and the inclusion or not of certain parameters into the analysis were investigated.
Following, we will summarize and explain the content of each test.
• TEST.A1: using original data;
• TEST.A2: replacing bladder neck D0.5cc missing values by zero;
• TEST.A3: replacing the Qmax missing values by the correspondent group median and using 15 ml/s as
Qmax cut-o value;
• TEST.A4: replacing the Qmax missing values by the correspondent group median and using 10 ml/s as
Qmax cut-o value;
• TEST.A5: not replacing the Qmax missing values and using 15 ml/s as Qmax cut-o value;
• TEST.A6: not replacing Qmax and using 10 ml/s as Qmax cut-o value;
• TEST.A7: replacing Qmax by the global median (overall median) and using 15 ml/s as Qmax cut-o
value;
• TEST.A8: replacing Qmax by the global median and using 10 ml/s as Qmax cut-o value.
Aer all these tests and according to the results, bladder D25 was transformed in categorical variable.
For this reason more tests were performed.
• TEST.A9: testing 30% of PD for bladder D25, replacing Qmax missing values by the global median and
using 10 ml/s as Qmax cut-o value.
• TEST.A10: testing 30% of PD for bladder D25, replacing Qmax missing values by the correspondent
group median and using 10 ml/s as Qmax cut-o value.
• TEST.A11: testing 30% of PD for bladder D25, replacing Qmax missing values by the global median
and using 15 ml/s as Qmax cut-o value.
• TEST.A12: testing 30% of PD for bladder D25, replacing Qmax missing values by the correspondent
group median and using 15 ml/s as Qmax cut-o value.
• TEST.A13: replacing Qmax missing values by using single imputation EM and using 10 ml/s as Qmax
cut-o value;
• TEST.A14: using multiple imputation for Qmax missing values and using 10 ml/s as Qmax cut-o
value; .
• TEST.A15: testing other cut-o values for bladder D25 as 28%, 32%, 35% of PD.
As last, other DVH parameters of bladder neck were analysed.
• TEST.A16: Investigating on univariate analysis bladder neck D5, D10, D15, D20 and D30.
e second step on this part was to apply Method B. e main objective of this methodology was to
investigate whether the nal results will be the same or not using dierent statistical approach. Like in the
previous step, we did some tests which will be described below.
• TEST.B1: Applying Chi-square and Mann-Whitney test. According to the results evaluate those pa-
rameters on MVA using confounders without replacing the missing values;
• TEST.B2: Investigating the cut-o values of parameters showing statistical signicance without re-
placing the Qmax missing values.
• TEST.B3: Applying TEST.B1 and TEST.B2 approach but replacing the missing values. e missing
values are replaced using MCMC MI.
• TEST.B4: Cross validation using ROC curve analysis.
Method A (TEST.A1-TEST.A16) was applied only in small group, while Method B (TEST.B1-TEST.B4)
was performed in small and large group.
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4.3 Results
In this section, the results related to the small and large group will be reported. Firstly, we will show
the results using a small data set and then using a large sample. Within these subsections, the results will be
show according to the methodology described in subsection 4.2.5.
4.3.1 Small Group
TEST.A1 + TEST.A2
e rst experiment was to use the original data without replacing any missing values. Only variables
that achieved p-value ≤ 0.2 are represented in the table 4.4. Other variables were included on univariate
analysis but they were not found statistically signicant. e complete results are in Appendix D.
e next step was to include all variables on multivariate analysis, but because of missing values in
some parameters (bladder neck D0.5cc and Qmax), SPSS did not achieve the best model reporting convergence
problems (it only use 64.3% of the data). In this way, it was not possible to perform the analysis
Aerwards, the missing values of bladder neck D0.5cc were replaced by 0 and it xed the convergence
problems (TEST.A2). On the other hand, replacing bladder neck D0.5cc by 0 does not make sense because
these missing values are not a missing values caused by losing some patient le. In this case, the bladder neck
is a small structure and some patients did not have that volume. erefore, we decided to exclude bladder
neck D0.5cc from the analysis because we cannot replace any value even using complex techniques.
e summarized outcome of univariate logistic regression is described in table 4.4.
Table 4.4: Summarized result of TEST.A1.
Univariate
Variables OR (95%CI) p-value
Bladder D1cc 1.08 (0.97-1.22) 0.144
Bladder D2cc 1.11 (0.98-1.27) 0.098
Bladder D25 1.25 (1.07-1.45) 0.005*
Bladder V75 3.36 (1.23-9.19) 0.018
Bladder V80 4.99 (1.13-22.03) 0.034
Bladder Neck D0.5cc 1.10 (0.96-1.27) 0.163
PUM V110 (cc) 71.37 (0.61-8354.1) 0.079
UM D0.5cc 1.09 (1.00-1.18) 0.043
UM V100 1.21 (0.99-1.47) 0.063
UM V100 (cc) 1.9E+8 (0.008-4.6E+18) 0.119
TRUS volume ≥ 40 cc 4.60 (1.11-19.14) 0.036
Qmax < 15 ml/s 3.61 (0.79-16.35) 0.096
IPSS ≥ 10 3.33 (0.73-15.27) 0.121
Needles ≥ 17 3.67 (0.84-16.04) 0.084
PTV volume ≥ 50 cc 2.89 (0.73-11.43) 0.132
Abbreviations: * Statistically signicant;
PUS = Prostatic Urethra Superior; PUM = Prostatic Urethra MID;
PUI = Prostatic Urethra Inferior; UM = Membranous Urethra;
OR = Odd ratio; 95% CI = 95 % Condence Interval.
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TEST.A3
In order to solve the convergence problems, Qmax missing values were replaced. e Qmax of the CAD
group showed a skewed distribution and for that reason the replacements were made using median rather
than mean. However, the Qmax of no-CAD showed a Gaussian distribution that means the median is roughly
equal to the mean.erefore, the median was used for both groups. Qmax missing values are distributed in
this way: 1 missing value in CAD group that was replaced by 9.3 and 3 missing values in no-CAD that were
replaced by 16.6. is technique allowed to run the univariate and multivariate analysis without convergence
problems. Applying this method, bladder D25, Qmax < 15 ml/s and IPSS ≥ 10 were statistically signicant
(see table 4.5). In other words, those variables might be related to the need of a bladder catheter aer treatment
due to AUR.
Table 4.5: Summarized result of TEST.A3.
Univariate Multivariate
Variables p-value p-value OR (95%CI)
Bladder D1cc 0.144 0.677 -
Bladder D2cc 0.098 0.691 -
Bladder D25 0.005 0.006* 1.32 (1.084-1.603)
Bladder V75 0.018 0.768 -
Bladder V80 0.034 0.807 -
PUM V110 (cc) 0.079 0.351 -
UM D0.5cc 0.043 0.333 -
UM V100 0.063 0.104 -
UM V100 (cc) 0.119 0.515 -
TRUS volume ≥ 40 cc 0.036 0.667 -
Qmax < 15 ml/s 0.036 0.039* 39.82 (1.20 -1325.86)
IPSS ≥ 10 0.121 0.021* 74.11 (1.91-2879.46)
Needles ≥ 17 0.084 0.104 -
PTV volume ≥ 50 cc 0.132 0.323 -
Abbreviations: * Statistically signicant;
PUS = Prostatic Urethra Superior; PUM = Prostatic Urethra MID;
PUI = Prostatic Urethra Inferior; UM = Membranous Urethra;
OR = Odd ratio; 95% CI = 95 % Condence Interval.
TEST.A4
In this test, the usage of another cut-o value for Qmax was investigated, namely 10ml/s. e same
technique in TEST.A3 to work with missing values was applied. As such in previous test, there were no
convergence problems. Using Qmax cut-o as 10 ml/s, multivariate method provided bladder D25, Qmax <
10ml/s and IPSS ≥ 10 as important predictors. Furthermore, the Qmax < 10 ml/s p-value was smaller than
Qmax < 15 ml/s p-value. erefore, Qmax < 10 ml/s seems to be stronger related to AUR than with Qmax <
15 ml/s. e results are presented in table 4.6.
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Table 4.6: Summarized result of TEST.A4.
Univariate Multivariate
Variables p-value p-value OR (95%CI)
Bladder D1cc 0.144 0.427 -
Bladder D2cc 0.098 0.362 -
Bladder D25 0.005 0.006* 1.34 (1.09-1.66)
Bladder V75 0.018 0.702 -
Bladder V80 0.034 0.780 -
PUM V110 (cc) 0.079 0.105 -
UM D0.5cc 0.043 0.336 -
UM V100 0.063 0.217 -
UM V100 (cc) 0.119 0.264 -
TRUS volume ≥ 40 cc 0.036 0.221 -
Qmax < 10 ml/s 0.025 0.020* 10.08 (1.44 – 70.54)
IPSS ≥ 10 0.121 0.021* 16.73 (1.53 – 183.29)
Needles ≥ 17 0.084 0.209 -
PTV volume ≥ 50 cc 0.132 0.624 -
Abbreviations: * Statistically signicant;
PUS = Prostatic Urethra Superior; PUM = Prostatic Urethra MID;
PUI = Prostatic Urethra Inferior; UM = Membranous Urethra;
OR = Odd ratio; 95% CI = 95 % Condence Interval.
TEST.A5 + TEST.A6
In TEST.A5, univariate and multivariate analysis were performed using the dataset without Qmax
missing value replacements. SPSS did not report convergence problems and did not nd any statistically
signicant variables either. SPSS used only 90.5% of the data and because of the small sample size losing
patients has an important impact on results. In TEST.A6, only Qmax cut-o value was changed to 10 ml/s.
e MVA output reported again statistically signicant variables (bladder D25 and IPSS ≥ 10). e result are
presented in table 4.7.
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Table 4.7: Summarized result of TEST.A6.
Univariate Multivariate
Variables p-value p-value OR (95%CI)
Bladder D1cc 0.144 0.479 -
Bladder D2cc 0.098 0.412 -
Bladder D25 0.005 0.006* 1.33 (1.08-1.63)
Bladder V75 0.018 0.674 -
Bladder V80 0.034 0.759 -
PUM V110 (cc) 0.079 0.164 -
UM D0.5cc 0.043 0.360 -
UM V100 0.063 0.218 -
UM V100 (cc) 0.119 0.259 -
TRUS volume ≥ 40 cc 0.036 0.259 -
Qmax < 10 ml/s 0.072 0.071 -
IPSS ≥ 10 0.121 0.044* 19.12 (1.08-338.01)
Needles ≥ 17 0.084 0.288 -
PTV volume ≥ 50 cc 0.132 0.820 -
Abbreviations: * Statistically signicant;
PUS = Prostatic Urethra Superior; PUM = Prostatic Urethra MID;
PUI = Prostatic Urethra Inferior; UM = Membranous Urethra;
OR = Odd ratio; 95% CI = 95 % Condence Interval.
TEST.A7 + TEST.A8
In these tests, Qmax missing values were replaced by the overall median (13.25) instead of by the
correspondent group median. In TEST.A7 and TEST.A8 (see tables 4.8 and 4.9, respectively), Qmax cut-o
value 15 ml/s and 10 ml/s was used, respectively. Once again, when the Qmax < 10 ml/s was tested, the
results recovered outcome obtained in TEST.A3.
Table 4.8: Summarized result of TEST.A7.
Univariate Multivariate
Variables p-value p-value OR (95%CI)
Bladder D1cc 0.144 0.611 -
Bladder D2cc 0.098 0.626 -
Bladder D25 0.005 0.008* 1.31 (1.07-1.60)
Bladder V75 0.018 0.697 -
Bladder V80 0.034 0.770 -
PUM V110 (cc) 0.079 0.210 -
UM D0.5cc 0.043 0.606 -
UM V100 0.063 0.165 -
UM V100 (cc) 0.119 0.833 -
TRUS volume ≥ 40 cc 0.036 0.624 -
Qmax < 15 ml/s 0.125 0.113 -
IPSS ≥ 10 0.121 0.029* 15.76 (1.34-186.05)
Needles ≥ 17 0.084 0.081 -
PTV volume ≥ 50 cc 0.132 0.427 -
Abbreviations: * Statistically signicant;
PUS = Prostatic Urethra Superior; PUM = Prostatic Urethra MID;
PUI = Prostatic Urethra Inferior; UM = Membranous Urethra;
OR = Odd ratio; 95% CI = 95 % Condence Interval.
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Table 4.9: Summarized result of TEST.A8.
Univariate Multivariate
Variables p-value p-value OR (95%CI)
Bladder D1cc 0.144 0.419 -
Bladder D2cc 0.098 0.333 -
Bladder D25 0.005 0.007* 1.31 (1.08-1.59)
Bladder V75 0.018 0.736 -
Bladder V80 0.034 0.807 -
PUM V110 (cc) 0.079 0.092 -
UM D0.5cc 0.043 0.265 -
UM V100 0.063 0.211 -
UM V100 (cc) 0.119 0.246 -
TRUS volume ≥ 40 cc 0.036 0.131 -
Qmax < 10 ml/s 0.066 0.044* 6.83 (1.05-44.45)
IPSS ≥ 10 0.121 0.019* 18.34 (1.60-209-99)
Needles ≥ 17 0.084 0.134 -
PTV volume ≥ 50 cc 0.132 0.444 -
Abbreviations: * Statistically signicant;
PUS = Prostatic Urethra Superior; PUM = Prostatic Urethra MID;
PUI = Prostatic Urethra Inferior; UM = Membranous Urethra;
OR = Odd ratio; 95% CI = 95 % Condence Interval.
TEST.A9 + TEST.A10
In both these test, the rst experiment was to transform the bladder D25 in a categorical variable. It
is interesting to know what is the dose threshold that might be associated to the needing of bladder catheter
aer treatment. e cut-o value (30% of PD) for bladder D25 was chosen according to medical experience
and data distribution through that variable. In both tests, 10 ml/s was used as cut-o value for Qmax. e
dierence between tests is the technique to work with missing values. In TEST.A9 and TEST.A10, the missing
values were replaced using global median and subgroup median techniques, respectively. Bladder D25≥ 30%
only showed p ≤ 0.05 in TEST.A10. e outcome of these tests are shown in table 4.10 and 4.11.
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Table 4.10: Summarized result of TEST.A9.
Univariate Multivariate
Variables p-value p-value OR (95%CI)
Bladder D1cc 0.144 0.737 -
Bladder D2cc 0.098 0.855 -
Bladder D25 ≥ 30% of PD 0.023 0.148 -
Bladder V75 0.018 0.022* 5.61 (1.29-24.41)
Bladder V80 0.034 0.199 -
PUM V110 (cc) 0.079 0.056 -
UM D0.5cc 0.043 0.266 -
UM V100 0.063 0.163 -
UM V100 (cc) 0.119 0.225 -
TRUS volume ≥ 40 cc 0.036 0.103 -
Qmax < 10 ml/s 0.066 0.027* 8.44 (1.27-56.22)
IPSS ≥ 10 0.121 0.026* 13.59 (1.37-134.76)
Needles ≥ 17 0.084 0.152 -
PTV volume ≥ 50 cc 0.132 0.604 -
Abbreviations: * Statistically signicant;
PUS = Prostatic Urethra Superior; PUM = Prostatic Urethra MID;
PUI = Prostatic Urethra Inferior; UM = Membranous Urethra;
OR = Odd ratio; 95% CI = 95 % Condence Interval.
Table 4.11: Summarized result of TEST.A10.
Univariate Multivariate
Variables p-value p-value OR (95%CI)
Bladder D1cc 0.144 0.264 -
Bladder D2cc 0.098 0.275 -
Bladder D25 ≥ 30% of PD 0.023 0.031* 26.73 (1.35-529.48)
Bladder V75 0.018 0.321 -
Bladder V80 0.034 0.438 -
PUM (cc) 0.079 0.050 -
UM D0.5cc 0.043 0.675 -
UM V100 0.063 0.141 -
UM V100 (cc) 0.119 0.374 -
TRUS volume ≥ 40 cc 0.036 0.561 -
Qmax < 10 ml/s 0.025 0.023* 13.13 (1.43-120.85)
IPSS ≥ 10 0.121 0.013* 53.48 (2.35-1217.46)
Needles ≥ 17 0.084 0.191 -
PTV volume ≥ 50 cc 0.132 0.870 -
Abbreviations: * Statistically signicant;
PUS = Prostatic Urethra Superior; PUM = Prostatic Urethra MID;
PUI = Prostatic Urethra Inferior; UM = Membranous Urethra;
OR = Odd ratio; 95% CI = 95 % Condence Interval.
TEST.A11 + TEST.A12
e procedure for bladder D25, in TEST.A11 and TEST.A12, was equal to the previous test, but Qmax
cut-o was changed to 15 ml/s. Based on these results and according to TEST.A3 + TEST.A4 and TEST.A7 +
TEST.A8 results, Qmax < 10 ml/s seems to be a beer risk factor for CAD due to AUR than Qmax < 15 ml/s.
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Table 4.12 and 4.13 summarize the results in this stage.
Table 4.12: Summarized result of TEST.A11.
Univariate Multivariate
Variables p-value p-value OR (95%CI)
Bladder D1cc 0.144 0.279 -
Bladder D2cc 0.098 0.284 -
Bladder D25 ≥ 30% of PD 0.023 0.029* 20.26 (1.36-301.85)
Bladder V75 0.018 0.289 -
Bladder V80 0.034 0.419 -
PUM V110 (cc) 0.079 0.050 -
UM D0.5cc 0.043 0.978 -
UM V100 0.063 0.129 -
UM V100 (cc) 0.119 0.858 -
TRUS volume ≥ 40cc 0.036 0.882 -
Qmax < 15 ml/s 0.125 0.169 -
IPSS ≥ 10 0.121 0.028* 32.98 (1.46-744.60)
Needles ≥ 17 0.084 0.090 -
PTV volume ≥ 50 cc 0.132 0.790 -
Abbreviations: * Statistically signicant;
PUS = Prostatic Urethra Superior; PUM = Prostatic Urethra MID;
PUI = Prostatic Urethra Inferior; UM = Membranous Urethra;
OR = Odd ratio; 95% CI = 95 % Condence Interval.
Table 4.13: Summarized result of TEST.A12.
Univariate Multivariate
Variables p-value p-value OR (95%CI)
Bladder D1cc 0.144 0.894 -
Bladder D2cc 0.098 0.953 -
Bladder D25 ≥ 30% of PD 0.023 0.364 -
Bladder V75 0.018 0.021* 5.03 (1.28-19.77)
Bladder V80 0.034 0.296 -
PUM V110 (cc) 0.079 0.112 -
UM D0.5cc 0.043 0.730 -
UM V100 0.063 0.210 -
UM V100 (cc) 0.119 0.467 -
TRUS volume ≥ 40 cc 0.036 0.284 -
Qmax < 15 ml/s 0.036 0.044* 23.35 (1.09-501.17)
IPSS ≥ 10 0.121 0.063 -
Needles ≥ 17 0.084 0.137 -
PTV volume ≥ 50 cc 0.132 0.854 -
Abbreviations: * Statistically signicant;
PUS = Prostatic Urethra Superior; PUM = Prostatic Urethra MID;
PUI = Prostatic Urethra Inferior; UM = Membranous Urethra;
OR = Odd ratio; 95% CI = 95 % Condence Interval.
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TEST.A13
In this test, the usage of a more complex technique to handle with missing values was investigated,
namely, single imputation using EM. First of all, Qmax was tested if it would be classied as MCAR and SPSS
soware has one test to do that. e MCAR test outcome was: Chi-Square = 8.729 and p-value = 0.366; that
means the assumption of MCAR was met because p-value> 0.05. To impute the missing values, this technique
uses the relationships between variables and because of that assumption the complete list of clinical variables
to impute missing values on Qmax was used. Aerwards, univariate and multivariate logistic regression were
applied. In this test, bladder D25≥ 30% of PD, Qmax< 10 ml/s and IPSS were statistically signicant and this
result is in agreement with the TEST.A8 and TEST.A9 (see table 4.14).
Table 4.14: Summarized result of TEST.A13.
Univariate Multivariate
Variables p-value p-value OR (95%CI)
Bladder D1cc 0.144 0.223 -
Bladder D2cc 0.098 0.231 -
Bladder D25 ≥ 30% of PD 0.023 0.029* 29.56 (1.41-621.51)
Bladder V75 0.018 0.277 -
Bladder V80 0.034 0.380 -
PUM V110 (cc) 0.079 0.056 -
UM D0.5cc 0.043 0.757 -
UM V100 0.063 0.155 -
UM V100 (cc) 0.119 0.456 -
TRUS volume ≥ 40 cc 0.036 0.426 -
Qmax < 10 ml/s 0.046 0.048* 8.71 (1.02-74.46)
IPSS ≥ 10 0.121 0.016* 33.84 (1.91-600.55)
Needles ≥ 17 0.084 0.115 -
PTV volume ≥ 50 cc 0.132 0.682 -
Abbreviations: * Statistically signicant;
PUS = Prostatic Urethra Superior; PUM = Prostatic Urethra MID;
PUI = Prostatic Urethra Inferior; UM = Membranous Urethra;
OR = Odd ratio; 95% CI = 95 % Condence Interval.
TEST.A14
Multiple imputation like single imputation can only be used when the variables with missing values
meet MCAR test and previous test conrmed that. Multiple Imputation has more than one technique to impute
the missing values and Automatic and MCMC method were used in this test. ose methods are described in
chapter 2 section 2.3. In both methods 5 iterations were used. erefore, in TEST.A14 both method of multiple
imputation were under investigation. e automatic method outcome showed bladder V75, Qmax < 10 ml/s
and IPSS as statistically signicant and bladder D25 ≥ 30% of PD lost its signicance. e summarized result
is shown in table 4.15.
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Table 4.15: Summarized result of Automatic MI.
Univariate Multivariate
Variables p-value p-value OR (95%CI)
Bladder D1cc 0.144 0.737 -
Bladder D2cc 0.098 0.855 -
Bladder D25 ≥ 30% of PD 0.023 0.148 -
Bladder V75 0.018 0.022* 5.61 (1.29-24.41)
Bladder V80 0.034 0.199 -
PUM V110 (cc) 0.079 0.056 -
UM D0.5cc 0.043 0.266 -
UM V100 0.063 0.163 -
UM V100 (cc) 0.119 0.225 -
TRUS volume ≥ 40 cc 0.036 0.103 -
Qmax < 10 ml/s 0.066 0.027* 8.44 (1.27-56.22)
IPSS ≥ 10 0.121 0.026* 13.59 (1.37-134.76)
Needles ≥ 17 0.084 0.152 -
PTV volume ≥ 50 cc 0.132 0.604 -
Abbreviations: * Statistically signicant;
PUS = Prostatic Urethra Superior; PUM = Prostatic Urethra MID;
PUI = Prostatic Urethra Inferior; UM = Membranous Urethra;
OR = Odd ratio; 95% CI = 95 % Condence Interval.
e MCMC MI output showed again bladder D25 ≥ 30% of PD, Qmax < 10 ml/s and IPSS ≥ 10 as
factors associated with AUR, in accordance with TEST.A8 and TEST.A10. is result is shown in table 4.16.
Table 4.16: Summarized result of MCMC MI.
Univariate Multivariate
Variables p-value p-value OR (95%CI)
Bladder D1cc 0.144 0.223 -
Bladder D2cc 0.098 0.231 -
Bladder D25 ≥ 30% of PD 0.023 0.029* 29.56 (1.41-621.51)
Bladder V75 0.018 0.277 -
Bladder V80 0.034 0.380 -
PUM V110 (cc) 0.079 0.056 -
UM D0.5cc 0.043 0.757 -
UM V100 0.063 0.155 -
UM V100 (cc) 0.119 0.456 -
TRUS volume ≥ 40 cc 0.036 0.426 -
Qmax < 10 ml/s 0.066 0.048* 8.71 (1.02-74.46)
IPSS ≥ 10 0.121 0.016* 33.84 (1.91-600.55)
Needles ≥ 17 0.084 0.115 -
PTV volume ≥ 50 cc 0.132 0.682 -
Abbreviations: * Statistically signicant;
PUS = Prostatic Urethra Superior; PUM = Prostatic Urethra MID;
PUI = Prostatic Urethra Inferior; UM = Membranous Urethra;
OR = Odd ratio; 95% CI = 95 % Condence Interval.
Table 4.17 will summarize the result of dierent methods to impute missing values. MCMC MI is the
most suitable method to impute missing values. However, median group substitution seems to be a simple
method to replace few missing values in small datasets.
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Table 4.17: Comparison between Imputation Methods.
Multivariate Logistic Regression
Method
Variables
Subgroup median
p-value
Overall median
p-value
Single Impuatation
p-value
Automatic MI
p-value
MCMC MI
p-value
Bladder D25 ≥ 30% PD 0.031 - 0.029 - 0.029
Qmax <10 ml/s 0.023 0.027 0.048 0.027 0.048
IPSS ≥ 10 0.013 0.026 0.016 0.026 0.016
Bladder V75 - 0.022 - 0.022 -
TEST.A15
According to the previous tests, bladder D25 ≥ 30% of PD is an important parameter associated with
CAD due to AUR. erefore, other cut-o values were evaluated, such as 28% of PD and 32% of PD. e
result was not expected: bladder D25 ≥ 28% and 32% of PD lost the signicance and other bladder parameter
(bladder V75 (% of PD)) pops-up (see in table 4.18). One possible interpretation is the population size. When
the cut-o value was changed, one or two patients switched over the group, that means small changes in our
dataset resulting in big eects on nal outcome.
Table 4.18: Summarized result of TEST.A15.
Univariate (p-value) Multivariate (p-value)
Bladder D25 ≥ 28% PD 0.075 0.277 –> bladder V75 (p=0.016)
Bladder D25 ≥ 30% PD 0.023 0.029
Bladder D25 ≥ 32% PD 0.034 0.750 –> bladder V75 (p=0.016)
TEST.A16
In TEST.A1, one parameter of bladder neck appeared statistically signicant on univariate method but
it was excluded from analysis because that variable contained many missing values. In this TEST.A16, other
DVH parameters were analysed in order to assess whether there is some relationship between AUR and dose
in bladder neck or not. On univariate method the following parameters were investigated: bladder neck D5,
D10, D15, D20 and D30.
In this test, bladder neck was not associated with CAD due to AUR aer treatment and the statistical
signicance observed in the rst test (TEST.A1) was thus a reective of missing values. e result is shown
in table 4.19.
Table 4.19: Summarized result of TEST.A16.
Univariate (p-value)
Bladder Neck D5 0.333
Bladder Neck D10 0.314
Bladder Neck D15 0.367
Bladder Neck D20 0.379
Bladder Neck D25 0.407
e following TESTS are related to results from application of a dierent statistical analysis method-
ology: Method B (see subsection 4.2.5).
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TEST.B1
In this test, the association between CAD due to AUR and clinical parameters was assessed using Chi-
square test or Fisher’s exact test. When the assumption of expected counts for Chi square (see 2.1.1) is broken
the result is a radical reduction in test power and the solution is the Fisher’s exact test. In this test, the Qmax
missing values were not replaced. e outcome is shown in table 4.20.
Table 4.20: Result of Chi-Square on TEST.B1.
CAD no-CAD
Clinical Parameters (n=14) (n =28) p-value
Qmax*** 0.084*
< 10 ml/s 7 (50%) 6 (21%)
≥ 10 ml/s 6 (43%) 19 (73%)
IPSS 0.113*
< 10 9 (64%) 24 (86%)
≥ 10 5 (36%) 4 (14%)
Age (years) 0.662**
≥ 70 6 (43%) 14 (50%)
< 70 8 (57%) 14 (50%)
PTV volume 0.125**
≥50 cc 10 (71%) 13 (46%)
< 50 cc 4 (29%) 15 (54%)
Needles 0.075**
≥17 11 (79%) 14 (50%)
< 17 3 (21%) 14 (50%)
Urinary residue 0.827**
≥ 30 ml 7 (50%) 13 (46%)
<30 ml 7 (50%) 15 (54%)
Urethra length 0.650*
≥ 50 mm 13 (93%) 24 (86%)
< 50 mm 1 (7%) 4 (4%)
TRUS volume 0.067*
≥ 40 cc 7 (50%) 5 (18%)
< 40 cc 7 (50%) 23 (82%)
Abbreviations:
CAD = patients with bladder catheter;
* According to Fisher’s exact test;
** According to Chi-square test;
*** 4 missing values: 1 case and 3 controls.
en, Mann-Whitney test was applied in order to investigate the relationship between DVH parame-
ters and CAD due to AUR. e outcome of this test is present in table 4.21.
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Table 4.21: Result of Mann-Whitney on TEST.B1.
CAD (n=14) no-CAD (n=28)
DVH Parameters Median Median p-value
Bladder D1cc (% of PD) 73.87 71.36 0.023*
Bladder D2cc (% of PD) 68.78 65.26 0.020*
Bladder D25 (% of PD) 37.00 29.60 0.002*
Bladder V75 (%) 1.08 0.45 0.012*
Bladder V80 (%) 0.42 0.09 0.017*
Bladder V75 (cc) 0.84 0.53 0.040*
Bladder V80 (cc) 0.38 0.14 0.038*
Bladder Neck D0.1cc (% of PD) 75.42 74.48 0.308
Bladder Neck V80 (%) 1.29 0.69 0.362
Bladder Neck V80 (cc) 0.02 0.01 0.272
PUS D0.1cc (% of PD) 113.29 113.52 0.864
PUS D30 (% of PD) 111.67 112.54 0.518
PUS V110 (%) 42.70 47.20 0.452
PUS V110 (cc) 0.24 0.23 0.535
PUM D0.1cc (% of PD) 115.50 115.35 0.553
PUM D30 (% of PD) 114.05 114.37 0.968
PUM V110 (%) 91.42 93.33 0.989
PUM V110 (cc) 0.49 0.44 0.101
PUI D0.1cc (% of PD) 112.85 112.99 0.683
PUI D30 (% of PD) 111.52 111.47 0.927
PUI V110 (%) 46.82 47.85 0.762
PUI V110 (cc) 0.29 0.23 0.452
UM D0.1cc (% of PD) 90.11 89.19 0.782
UM D0.5cc (% of PD) 57.31 52.71 0.056
UM D30 (% of PD) 67.49 66.23 0.452
UM V100 (%) 0.98 0.86 0.947
UM V100 (cc) 0.01 0.01 0.702
Abbreviations:
* Statistically signicant; CAD = patients with bladder catheter;
PUS = Prostatic Urethra Superior; PUM = Prostatic Urethra Mid;
PUI = Prostatic Urethra Inferior; UM = Membranous Urethra .
Clinical parameters, such as Qmax and DVH parameters with p-values ≤ 0.5 or close to that value,
were selected to evaluate their relationship with CAD due to AUR using univariate and multivariate logistic
regression. To investigate whether these parameters are independent factors or not, multivariate logistic
regression was performed adjusted by the following confounder: IPSS, age, needles, PTV volume and urinary
residue. Qmax < 10 ml/s, bladder D25 and UM D0.5cc retained their signicance aer performing MVA.
However, only the ORs of bladder D25 and UM D0.5cc did not change substantially aer adjustment for the
confounders indicating that there was no confounding, while the ORs of Qmax< 10 ml/s changed. e result
of this test is shown in table 4.22.
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Table 4.22: UVA and MVA result of TEST.B1.
UVA MVAγ
Parameters OR (95% CI) p-value OR (95% CI) p-value
Qmax < 10 ml/s 3.69(0.88-15.37) 0.072 6.06 (1.18-31.1) 0.031*
Bladder D2cc 1.11 (0.98-1.27) 0.098 - 0.075
Bladder D25 1.25 (1.07-1.45) 0.005 1.34 (1.01-1.63) 0.004*
Bladder V75 (cc) - 0.260 - -
Bladder V80 (cc) - 0.371 - -
UM D0.5cc 1.09 (1.00-1.181) 0.043 1.17 (1.02-1.34) 0.029*
Abbreviations:
* Statistically signicant; OR = Odd ratio; 95% CI = 95% Condence interval;
γ Ajusted by IPSS, needles, age, urinary residue and PTV volume.
TEST.B2
In accordance with the results, it is interesting to know what the dose threshold is for bladder D25 and
membranous urethra D0.5cc, like was performed in Method A. Chi-square/ Fisher’s exact test was applied to
assess the relationship between CAD due to AUR and dierent cut-o values for both parameters. Bladder
D25 ≥ 30% and 35% of PD and membranous urethra D0.5cc ≥ 55% of PD were statistically signicant, but
only the ORs of bladder D25 ≥ 35% of PD did not change substantially aer adjustment for the confounders
indicating that there was no confounding. e outcomes are presented in tables 4.23 and 4.24.
Table 4.23: Result of bladder D25 cut-o points.
cut-o values UVA MVAγ
Bladder D25 p-value Parameters OR (95% CI) p-value OR (95% CI) p-value
40% of PD 0.032* Bladder D25 ≥ 40% of PD - 0.999 -
35% of PD 0.036* Bladder D25 ≥ 35% of PD 4.89 (1.22-19.65) 0.025 5.13 (1.18-22.28) 0.029
30% of PD 0.014** Bladder D25 ≥ 30% of PD 6.92 (1.30-36.82) 0.023 18.09 (1.75-187.3) 0.015
25% of PD 0.283* - - - - -
Abbreviations:* According to Fisher’s exact test; ** According to Chi-square test; OR = Odd ratio;
95% CI = 95% Condence interval; γ Adjusted for IPSS, needles, age, urinary residue and PTV volume.
Table 4.24: Result of membranous urethra D0.5cc cut-o points.
cut-o values UVA MVAγ
UM D0.5cc p-value Parameters OR (95% CI) p-value OR (95% CI) p-value
40% of PD 0.545* - - - -
45% of PD 0.233* - - - -
50% of PD 0.495** - - - -
55% of PD 0.013** UM D00.5cc ≥ 55% of PD 5.40 (1.35-21.64) 0.017 20.65 (2.21-192.74) 0.008
60% of PD 0.197* UM D00.5cc ≥ 60% of PD - 0.157 -
65% of PD 0.100* UM D00.5cc ≥ 65% of PD - 0.099 -
Abbreviations:* According to Fisher’s exact test; ** According to Chi-square test; OR = Odd ratio;
95% CI = 95% Condence interval; γ Adjusted for IPSS, needles, age, urinary residue and PTV volume.
TEST.B3
In this test, the same method of TEST.B1 was applied, but the Qmax missing values were replaced using
MCMC MI. erefore, Chi-square was performed for clinical parameters. e Mann-Whitney test is exactly
the same that was reported in TEST.B1. In this stage, the cut-o value analysis (bladder and membranous
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urethra ) do not change because the confounders do not have missing values. No considerable dierences
were registered and the results and conclusions are in agreement with TEST.B1.
Table 4.25: Result of Chi-Square on TEST.B3.
CAD no-CAD
Clinical Parameters (n=14) (n =28) p-value
Qmax 0.040**
< 10 ml/s 8 (57%) 7 (25%)
≥ 10 ml/s 6 (43%) 21 (75%)
IPSS 0.113*
< 10 9 (64%) 24 (86%)
≥ 10 5 (36%) 4 (14%)
Age (years) 0.662**
≥ 70 6 (43%) 14 (50%)
< 70 8 (57%) 14 (50%)
PTV volume 0.125**
≥50 cc 10 (71%) 13 (46%)
< 50 cc 4 (29%) 15 (54%)
Needles 0.075**
≥ 17 11 (79%) 14 (50%)
< 17 3 (21%) 14 (50%)
Urinary residue 0.827**
≥ 30 ml 7 (50%) 13 (46%)
< 30 ml 7 (50%) 15 (54%)
Urethra length 0.650*
≥ 50 mm 13 (93%) 24 (86%)
< 50 mm 1 (7%) 4 (4%)
TRUS volume 0.067*
≥ 40 cc 7 (50%) 5 (18%)
< 40 cc 7 (50%) 23 (82%)
Abbreviations:
CAD = patients with bladder catheter;
* According to Fisher’s exact test;
** According to Chi-square test.
Table 4.26: UVA and MVA result of TEST.B3.
UVA MVAγ
Parameters OR (95% CI) p-value OR (95% CI) p-value
Qmax < 10 ml/s 3.26 (0.76-14.01) 0.112 6.07 (1.28-28.81) 0.023*
Bladder D2cc 1.11 (0.98-1.27) 0.098 - 0.075
Bladder D25 1.25 (1.07-1.45) 0.005 1.34 (1.01-1.63) 0.004*
Bladder V75 (cc) - 0.260 - -
Bladder V80 (cc) - 0.371 - -
UM D0.5cc 1.09 (1.00-1.181) 0.043 1.17 (1.02-1.34) 0.029*
Abbreviations:
* Statistically signicant; OR = Odd ratio; 95% CI = 95% Condence interval;
γ Adjusted for IPSS, needles, age, urinary residue and PTV volume.
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TEST.B4
In this test, we evaluated the accuracy of our results and tested the validity of the selected median
cut-o values for the statistical signicant parameters: bladder D25, membranous urethra D0.5cc and Qmax.
Table 4.27 shows the AUC for each parameter and gure 4.2 presents the ROC curves. e cut-o points
were obtained through the coordinates points of the plot where the sensitivity is equal to the specicity (see
table 4.28). e result of this test conrm the validity of the cut-o points. erefore, our analysis predict the
increased risk of AUR beer than by chance.
Table 4.27: AUC analyses for each statistical signicant parameter.
AUC Std.Error Asymptotic Sig. 95% CI
Qmax 0.65 0.10 0.120 0.464-0.844
Qmax* 0.68 0.09 0.090 0.504-0.856
Bladder D25 0.79 0.07 0.003 0.644-0.933
UM D0.5cc 0.68 0.09 0.050 0.501-0.866
Notes: * missing values replaced by MCMC MI.
Figure 4.2: ROC curves for Qmax, bladder D25, membranous urethra D0.5cc.
Table 4.28: Comparison between ROC optimal cut-o points and previous cut-o points (TEST.B2).
Sensitivity Specicity Cut-o point Cut-o point(TEST.B2)
Qmax 0.77 0.72 12.6 ml/s 10 ml/s
Bladder D25 0.71 0.71 32.5% of PD 30/35% of PD
UM D0.5cc 0.64 0.64 54.5% of PD 55% of PD
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4.3.2 Large Group
According to the results achieved in the previous section and according to statistical guidelines, only
the Method B in this data set was applied .
First of all, in this dataset, there are more missing values and those are shown in table 4.29.
Table 4.29: Missing values distribution by variables.
Missing values N Percent
Qmax 54 25.70%
IPSS 42 20.00%
Age 1 0.50%
PTV volume 0 0.00%
Needles 0 0.00%
Urinary residue 43 20.50%
Urethra length 2 1.00%
TRUS volume 22 10.50%
TEST.B1
Firstly, the Mann-Whitney test was applied in order to evaluate the association between CAD due to
AUR and dosimetric parameters (table 4.30). en, clinical parameters were evaluated by using Chi-square
test or Fisher’s exact. e results are shown in table 4.31. Clinical and dosimetric variables with p-values <
0.05 were considered statistically signicant to include on univariate and multivariate analysis. In this case,
Qmax, bladder D25, bladder D10 were investigated in UVA and MVA adjusted for the following confounders:
IPSS, Age, needles, urinary residue and PTV volume. Qmax< 10 ml/s, bladder D25 and bladder D10 are shown
to be independent risk factor for CAD due to AUR aer treatment. e outcomes are displayed in table 4.32.
Table 4.30: Result of Mann-Whitney test on TEST.B1.
CAD no-CAD
DVH Parameters Median Median p-value
Bladder D1cc (% of PD) 76.79 74.21 0.174
Bladder D2cc (% of PD) 70.56 68.39 0.091
Bladder D25 (% of PD) 36.12 32.79 0.026*
Bladder D10 (% of PD) 51.15 47.98 0.012*
Bladder V75 (cc) 1.11 0.92 0.262
Bladder V80 (cc) 0.65 0.35 0.286
Urethra D1cc (% of PD) 109.59 109.17 0.543
Urethra D1 (% of PD) 117.88 119.27 0.098
Urethra D5 (% of PD) 116.95 116.22 0.908
Urethra V100 (cc) 0.95 0.95 0.700
Urethra V120 (cc) 0.01 0.01 0.227
Abbreviations: * Statistically signicant;
CAD = patients with bladder catheter.
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Table 4.31: Result of Chi-Square on TEST.B1.
CAD no-CAD
Clinical Parameters (n=14) (n =196) p-value
Qmax 0.017*
< 10 ml/s 7 (50%) 31 (16%)
≥ 10 ml/s 6 (43%) 112 (57%)
IPSS 0.528*
< 10 9 (64%) 114 (58%)
≥ 10 5 (36%) 40 (20%)
Age (years) 0.715**
≥ 70 6 (43%) 74 (38%)
< 70 8 (57%) 121 (62%)
PTV volume 0.564**
≥50 cc 10 (71%) 125 (64%)
< 50 cc 4 (29%) 71 (36%)
Needles 0.133**
≥17 11 (79%) 114 (58%)
< 17 3 (21%) 82 (42%)
Urinary residue 0.870**
≥ 30 ml 7 (50%) 73 (37%)
< 30 ml 7 (50%) 80 (41%)
Urethra length 1.00*
≥ 50 mm 13 (93%) 172 (88%)
< 50 mm 1 (7%) 23 (12%)
TRUS volume 0.134*
≥ 40 cc 7 (50%) 51 (26%)
< 40 cc 7 (50%) 123 (78%)
Abbreviations:
CAD = patients with bladder catheter;
* According to Fisher’s exact test;
** According to Chi-square test.
Table 4.32: UVA and MVA results of TEST.B1.
UVA MVAγ
Parameters OR (95%CI) p-value OR (95%CI) p-value
Qmax < 10 ml/s 4.22 (1.32-13.46) 0.015 4.62 (1.42-15.01) 0.011*
Bladder D25 1.01 (1.00-1.02) 0.019 1.01 (1.00-1.02) 0.017*
Bladder D10 1.01 (1.00-1.02) 0.019 1.01 (1.00-1.02) 0.019*
Abbreviations:
* Statistically signicant; OR = Odd ratio; 95% CI = 95% Condence interval;
γ Ajusted by IPSS, needles, age, urinary residue and PTV volume.
TEST.B2
According to the results in the previous test, cut-o values for bladder D25 and bladder D10 were
analysed. at relationship was assessed by using chi-square or Fisher’s exact test and aerwards the UVA
and MVA were performed to investigate possible confounders. Bladder D25 ≥ 30% of PD only showed a
tendency to correlate with CAD due to AUR. Regarding to bladder D10, only the cut-o value ≥ 50% PD
retained the signicance aer MVA adjusted for the confounders as independent factor because its OR did not
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change substantially. e outcomes for bladder D25 and D10 are shown in tables 4.33 and 4.34, respectively.
Table 4.33: Results of bladder D25 cu-o points.
cut-o values UVA MVAγ
Bladder D25 p-value Parameters OR (95%CI) p-value OR (95%CI) p-value
40% of PD 0.093* Bladder D25 ≥ 40% of PD 3.53 (0.88-14.12) 0.075 - 0.126
35% of PD 0.122** Bladder D25 ≥ 35% of PD 2.33 (0.77-6.98) 0.131 - 0.173
30% of PD 0.145** Bladder D25 ≥ 30% of PD 3.51 (0.76-16.14) 0.106 4.00 (0.86-18.58) 0.077
25% of PD 0.224* Bladder D25 ≥ 25% of PD - 0.998 - -
Abbreviations:* According to Fisher’s exact test; ** According to Chi-square test; OR = Odd ratio;
95% CI = 95% Condence interval; γ Adjusted for IPSS, needles, age, urinary residue and PTV volume.
Table 4.34: Results of bladder D10 cu-o points.
cut-o values UVA MVAγ
Bladder D10 p-value Parameters OR (95%CI) p-value OR (95%CI) p-value
35% of PD 0.371* - - - - -
40% of PD 0.077* - - - - -
45% of PD 0.179** Bladder D10 ≥ 45% of PD 2.39 (0.65-8.85) 0.191 - -
50% of PD 0.038** Bladder D10 ≥ 50% of PD 3.14 (1.01-9.75) 0.047 3.26 (1.03-10.30) 0.044
55% of PD 0.039** Bladder D10 ≥ 55% of PD 4.18 (1.19-14.80) 0.026 3.44 (0.93-12.70) 0.064
Abbreviations:* According to Fisher’s exact test; ** According to Chi-square test; OR = Odd ratio;
95% CI = 95% Condence interval; γ Adjusted for IPSS, needles, age, urinary residue and PTV volume.
TEST.B3
In this test, missing values were replaced by using MCMC MI. Qmax, IPSS and urinary residue were
the variables with a large amount of missing values and both of them were used in statistical analysis. Mann-
Whitney test did not change because those variables do not have missing values. Only Qmax met the p-value
< 0.05 (see table 4.35). Aer this test, Qmax, bladder D25 and bladder D10 were investigated on univariate and
multivariate method adjusted for the confounders. Both bladder D25, D10 and Qmax showed a relationship
as independent factors with CAD due to AUR aer treatment. Qmax < 10 ml/s was the most signicant
predictor of this side eect in this dataset.
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Table 4.35: Result of Chi-Square on TEST.B3.
CAD no-CAD
Clinical Parameters (n=14) (n =196) p-value
Qmax 0.008*
< 10 ml/s 8 (57%) 44 (22%)
≥ 10 ml/s 6 (43%) 152 (78%)
IPSS 0.531*
< 10 9 (64%) 149 (71%)
≥ 10 5 (36%) 61 (29%)
Age (years) 0.704**
≥ 70 6 (43%) 74 (38%)
< 70 8 (57%) 122 (62%)
PTV volume 0.564**
≥50 cc 10 (71%) 125 (64%)
< 50 cc 4 (29%) 71 (36%)
Needles 0.133**
≥ 17 11 (79%) 114 (58%)
< 17 3 (21%) 82 (42%)
Urinary residue 0.767**
≥ 30 ml 7 (50%) 106 (54%)
< 30 ml 7 (50%) 90 (46%)
Urethra length 1.00*
≥ 50 mm 13 (93%) 172 (88%)
< 50 mm 1 (7%) 23 (12%)
TRUS volume 0.132*
≥ 40 cc 7 (50%) 57 (29%)
< 40 cc 7 (50%) 139 (71%)
Abbreviations:
CAD = patients with bladder catheter;
* According to Fisher’s exact test;
** According to Chi-square test.
Table 4.36: UVA and MVA result of TEST.B3.
UVA MVAγ
Parameters OR (95%CI) p-value OR (95%CI) p-value
Qmax < 10 ml/s 4.31 (1.36-13.70) 0.013 4.61 (1.52-13.98) 0.007*
Bladder D25 1.01 (1.00-1.02) 0.019 1.01 (1.00-1.02) 0.019*
Bladder D10 1.01 (1.00-1.02) 0.019 1.01 (1.00-1.02) 0.019*
Abbreviations:
* Statistically signicant; OR = Odd ratio; 95% CI = 95% Condence interval;
γ Ajusted by IPSS, needles, age, urinary residue and PTV volume.
Once again, it is interesting to know what the dose threshold is for these parameters. According to
these results, bladder D25 ≥ 40% of PD showed only a tendency to associate with CAD due to AUR (see table
4.37). Bladder D10 ≥ 50% and 55% of PD have a relationship with this side eect, in this specic case, as
independent factor (4.38).
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Table 4.37: Results of bladder D25 cu-o points.
cut-o values UVA MVAγ
Bladder D25 p-value Parameters OR (95%CI) p-value OR (95%CI) p-value
40% of PD 0.093* Bladder D25 ≥ 40% of PD 3.53 (0.88-14.12) 0.075 - 0.06
35% of PD 0.122** Bladder D25 ≥ 35% of PD 2.33 (0.77-6.98) 0.131 - 0.122
30% of PD 0.145** Bladder D25 ≥ 30% of PD 3.51 (0.76-16.14) 0.106 - 0.106
25% of PD 0.224* Bladder D25 ≥ 25% of PD - 0.998 - -
Abbreviations:* According to Fisher’s exact test; ** According to Chi-square test; OR = Odd ratio;
95% CI = 95% Condence interval; γ Adjusted for IPSS, needles, age, urinary residue and PTV volume.
Table 4.38: Results of bladder D10 cu-o points.
cut-o values UVA MVAγ
Bladder D10 p-value Parameters OR (95%CI) p-value OR (95%CI) p-value
35% of PD 0.371* - - - - -
40% of PD 0.077* - - - - -
45% of PD 0.179** Bladder D10 ≥ 45% of PD 2.39 (0.65-8.85) 0.191 - -
50% of PD 0.038** Bladder D10 ≥ 50% of PD 3.14 (1.01-9.75) 0.047 3.14 (1.01-9.75) 0.047
55% of PD 0.039** Bladder D10 ≥ 55% of PD 4.18 (1.19-14.80) 0.026 4.18 (1.19-14.80) 0.026
Abbreviations:* According to Fisher’s exact test; ** According to Chi-square test; OR = Odd ratio;
95% CI = 95% Condence interval; γ Adjusted for IPSS, needles, age, urinary residue and PTV volume.
TEST.B4
In this test, cross validation was performed using ROC analysis such as for small group. Table 4.39
shows the AUC for each parameter and gure 4.3 presents the ROC curves. e cut-o points were obtained
through the coordinates points of the plot where the sensitivity is equal to the specicity (see table 4.40).
e result of this test is less optimistic (lower sensitivity and specicity (see table 4.40)) than for small
group because the large group has other GU and GI toxicities working as intrinsic confounders. In conclusion,
our statistical analysis predicts the increased risk of AUR beer than by chance (even for large group). e
cut-o analysis still shows roughly the same values as found in TEST.B2.
Table 4.39: AUC analyses for each statistically signicant parameter.
AUC Std.Error Asymptotic Sig. 95% CI
Qmax 0.65 0.077 0.078 0.497-0.799
Qmax* 0.67 0.072 0.037 0.526-0.808
Bladder D25 0.68 0.067 0.026 0.547-0.808
Bladder D10 0.70 0.068 0.012 0.568-0.833
Notes: * missing values replaced using MCMC MI
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Figure 4.3: ROC curves for Qmax, bladder D25 and bladder D10.
Table 4.40: Comparison between ROC optimal cut-o points and previous cut-o points (TEST.B2).
Sensitivity Specicity Cut-o point Cut-o point(TEST.B2)
Qmax 0.69 0.61 12.5 ml/s 10 ml/s
Bladder D25 0.51 0.51 34.2% of PD 30% of PD
Bladder D10 0.64 0.64 50.0% of PD 50% of PD
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4.4 Discussion
Patients treated with HDR BT usually have a long survival with 10 year biochemical recurrence free-
survival (bRFS) 3 > 90%. is underline the importance of reducing toxicity to improve quality of life (Qol) of
these patients. As AUR is a serious grade 3 toxicity for patients treated with HDR BT, exploring the predictive
clinical and dosimetric factors for AUR could improve Qol of those patients by reducing toxicity.
To the extent of our knowledge, this is the rst study to investigate the association between dosimetric
and clinical parameters and the occurrence of AUR (with the need for temporary CAD) in prostate cancer
treated with HDR BT as monotherapy. For this study, we compared the dosimetric and clinical variables of
the 14 PCa patients who needed a temporary CAD aer HDR BT with other 28 selected patients (with grade≤
1 GU and GI toxicities) treated with the same HDR BT regimen who did not need a CAD. We found that having
a pre-treatment baseline Qmax < 10 ml/s and dose to 25% of bladder volume exceeding 30%-40% of PD were
the two statistically signicant factors associated with increased risk of AUR. e statistical signicance of
these two parameters was conrmed when the dataset of these 14 CAD patients was compared to all available
patients (196) in our HDR BT monotherapy database who did not experience AUR. Furthermore, two dierent
statistical methods (Method A and B) were tested and used to perform the statistical analysis and dierent
methods were applied to deal with missing values. e usage of Method B and MCMC MI to deal with missing
values was robust and nally used for our nal results.
4.4.1 Imputation Methods & Methodology
Before embarking on the discussion of the results, some remarks have to be done regarding imputation
methods and statistical methodology used in our study.
Comparing the imputation methods in Method A, we conclude that the median substitution was a
good and simple technique to handle missing values in this specic case. However, choosing more complex
techniques, such as multiple imputation in case of a large amount of missing values could avoid biased out-
comes [27, 60, 61]. Table 4.17 shows the general comparison between dierent techniques to deal with missing
values. It can be concluded that the use of subgroup median substitution worked beer to replace missing
values than using overall median because we do not lose the population variance supporting previous ndings
[26].
When comparing more complex techniques (see table 4.17), such as Single Imputation EM, Automatic
MI and MCMC MI, the results were slightly dierent. Only Single Imputation and MCMC MI recovered the
same statistical parameters indicating that these are equivalent methods to impute missing values in small
datasets. However, as described in chapter 2, SPSS automatically selected the method to impute the missing
values, between monotone and MCMC MI methods, based on the paern of missing values. In this case, the
automatic method should have recovered the MCMC MI method because the missing values have an arbitrary
paern. erefore, the automatic method is an interesting tool but it can result in dierent outcomes. In
conclusion, evaluating clinical variables is challenging because the user is dependent on how complete that
information is.
In our study, we also investigated two dierent methodologies. Method A is a powerful statistical
method to analyse large dataset with large amount of events versus controls. In our case, the problem is
the low number of AUR cases even when we use the entire cohort of patients. ere is one role to apply
the logistic regression method: 1 covariate per 10 events. For this reason, the Method A gives us unreliable
conclusions because we included in the multivariate method more than 1 covariate. More clearly, that eect
easily can be seen looking at large condence intervals obtained by using Method A. On the other hand, in
the Method B, we only looked at one variable in the multivariate method adjusted for the confounders. is
seems to be more suitable for this study providing more reliable results. In conclusion, our study suggests the
3bRFS: means that aer undergoing prostate cancer treatment, the patient PSA level does not rise signicantly. If the patient
relapse biochemically (PSA rises), it is a reasonable indicator of who will develop a recurrent prostate cancer
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use of Method B and MCMC MI to impute missing values for datasets where a parameter with a low incidence
rate is being investigated.
4.4.2 Acute Urinary Retention
Clinical Parameters
In this study, the importance of baseline function as selection criteria is illustrated by one of baseline
clinical parameters selected. In our results, only the baseline Qmax was statistically associated with greater
risk of AUR, this is in accordance with data from a previous study from ErasmusMC - Cancer Institute [13]. In
that study the toxicity of the same group of patients was reported. Baseline urinary ow (Qmax)> 15 ml/s (p
= 0.047) was signicantly correlated with lower incidence of grade 2 or higher acute GU toxicity. In our re-
sults, Qmax< 10 ml/s was associated with AUR, which is a grade 3 acute GU toxicity. Qmax appeared in both
methods (Method A and B) as factor associated with AUR, but it is important to highlight the fact that Qmax
is not an independent factor according to the Method B –Small group because its OR changed aer adjust-
ment for the confounders(IPSS, needles, age, urinary residue and PTV volume). Lower baseline Qmax could
be related to urinary symptoms and urinary dysfunction before treatment. ose patients with low Qmax
reported mostly high IPSS and low urinary residue indicating limitations in daily functioning. erefore, this
strong correlation between Qmax and IPSS and urinary residue could explain the non-independence of Qmax
observed in Method B –Small group. Qmax missing values were a limitation in our study. However, when
missing data were replaced using MCMC MI, the results did not change substantially, and Qmax sustained as
independent factor. Furthermore, ROC curve for Qmax showed that Qmax predicts well the correlation with
AUR (beer than by chance, AUC = 0.65/0.68). Additionally, the optimal cut-o value determined by ROC
curve was 12.6ml/s which is not substantially dierent from 10ml/s. erefore, ROC curve analysis validated
the accuracy of this result. In conclusion, lower Qmax represents a pre-existing dysfunction and the cut-o
point we dened, 10 ml/s, is helpful in selection patients for HDR BT monotherapy.
High scores of baseline International Prostate Symptom Score have been reported in several LDR BT
studies [39, 40, 41] as predictor of AUR aer treatment. In the previous study [13] IPSS≥ 12 (p = 0.074) showed
a tendency to correlate with grade 2 or higher late GU toxicity aer HDR BT. In our current study, IPSS ≥ 10
showed statistical signicance on multivariate analysis in Method A. is is consistent with the previous LDR
BT studies mentioned. However, in Method B, IPSS did not achieve the p-value to consider as independent
variable to investigate on multivariate analysis and it was used as confounder factor. It suggests that IPSS
is less sensitive for AUR, which is an acute GU toxicity and not late GU toxicity. Additionally, baseline IPSS
already is a patient selection criteria for this treatment. Patients with baseline IPSS > 15/35 are rejected. is
might indicate that the actual IPSS constraint is suitable and we do not expect an increased risk of AUR.
Several LDR BT studies addressed AUR and reported the following clinical and treatment related pa-
rameters; number of needles [42, 62], prostate volume [42, 43, 44, 40, 41] or hormone therapy [62] as statis-
tically signicant factors correlated with high risk of AUR. In our group of patients number of needles and
prostate volume did not show a signicant p-values (≤ 0.05). In HDR BT the number of needles used is usually
lower than that used for LDR BT, e.g. 17/18 [35, 13](in average) for HDR BT and 22/25 [45, 62] for LDR BT,
which are related with less mechanical damage. It could explain the non-signicance of number of needles
in our study. Recently, [63, 64], a correlation between prostate volume (> 50 cc) and late genitourinary is
reported for EBRT. Prostate volume > 50 cc is excluded for HDR BT regimen and we did not expect a volume
eect on AUR.
DVH Parameters – Small Group
ere are no studies evaluating DVHs parameters for HDR BT as monotherapy. In both methods,
Method A and B, bladder D25 was a new predictor of AUR. is makes our ndings clinically important such
that one needs to restrict the dose to the bladder and that new sharper constraints should be applied.
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Using method B, a dose to 25% of bladder volume exceeding 30%-35% of PD (11.4Gy-13.3Gy, in case of
schedule 9.5Gy in 4 fractions) were statistically correlated with increased risk to develop AUR aer treatment.
However, only bladder D25 ≥ 35% of PD can be considered as independent factor because when we investi-
gated the association on MVA adjusted for the confounders, the OR did not change considerably that allows
the conclusion of independent factor. In the small dataset is hard to dene a cut-o value, that explains the
slight dierences in independency for bladder D25≥ 35% of PD and bladder D25≥ 30% of PD. However, ROC
curve analysis conrmed the strong relationship between bladder D25 and AUR (AUC = 0.79). Furthermore,
the optimal cut-o point from ROC curve was 32.5% of PD and we previously found 30%/35% of PD as cut-o
values, which might also explain the non-independence for bladder D25 ≥ 30% of PD. In literature, bladder
dose constraints are related to high dose regions. It is already known that D1cc of bladder exceeding 80% of
PD increase the risk of GU toxicity and it is commonly used as treatment constraint [12]. Peters at el. [65] re-
ported bladder D2cc≤ 70Gy constraint could reduce the risk on late GU toxicity aer LDR BT. In conclusion,
because the HDR treatment is given in very short period of time (36 hours) compared to 3 months in LDR,
the role of lower dose in predicting toxicity is expected.
ere is some hypothesis defending that the bladder trigone (bladder neck) plays an important role
in voiding mechanism. Irritation or injury to the bladder trigone may lead to urinary retention [46, 66]. In
our study, a possible relationship between dose to bladder neck and occurrence of AUR was not statistically
signicant. In contrast, Roelozen et al. [45] and Hathout et al. [46] reported dose to bladder neck as
an important predictor of AUR aer LDR BT. First, the correlation between AUR and bladder neck dosimetry
observed in previous studies could be due to large variation in dose to OAR during the LDR BT compared with
HDR BT, because the prostate size is being reduced over the time by retraction of edema or even due to organ
movements. Second, the presence of relatively high dose in bladder neck implies that at least some seeds
have been placed in the bladder muscle or due to seed migration’s phenomenon. erefore, the dosimetric
accuracy of HDR compared to LDR could explain the lack of correlation between dose to bladder neck and
AUR in our data. Other limitations are; the small sample size in our group and the great variation in the exact
denition/delineation of bladder neck, which could bias the results.
Regarding all dierent regions of urethra in this analysis, only membranous urethra D0.5cc, particu-
larly 0.5cc of volume exceeding 55% of PD, seems to be correlated with CAD due to AUR using the Method B.
However, its OR changed aer adjustment for the confounders on MVA indicating non-independency. So, we
can say that parameter might have some association with AUR but that small sample size makes it dicult
to nd a statistically signicant correlation. Dı´ez et al. [38] investigated the association between urethral
strictures and dierent regions of urethra volume aer HDR BT treatment (in four dierent treatment sche-
dules, 34Gy in 4fr, 36Gy in 4fr, 31.5Gy in 4fr and 26Gy in 2fr). ey identied 10 strictures in 213 patients
and they found no correlations between volumetric and dosimetric urethra (including membranous urethra
) parameters with that side eect. Our study suggests membranous urethra D0.5cc ≥ 55% of PD might have
some association with AUR but its statistical power could not be conrmed in the large group because of lack
of data on dierent areas of urethra in our database. However, ROC curve for UM D0.5cc showed that variable
predicts well the relationship with AUR (AUC = 0.68). e optimal cut-o value (54.5% of PD) determined by
ROC curve supported our ndings.
DVH parameters - Large group
In the large group, we only applied Method B and MCMC MI to impute missing values. In this group of
patients, bladder D25≥ 30% of PD (p = 0.077) showed only a tendency to associate with AUR. However, when
Qmax, IPSS and urinary residue missing values were replaced, bladder D25 ≥ 30% of PD lost its statistical
signicance for bladder D25 ≥ 40% of PD. is results might translate the inuence of missing values when
we are doing statistical analysis. Another possible reason was the way how we selected the control’s group in
this large dataset. We did not restrict the controls to have grade≤ 1 GU and/or GI toxicities and we took into
account all patients without CAD but they might have other toxicities playing a role as intrinsic confounders
explaining only the tendency to associate with. Even so, it suggests that the bladder D25 receiving ≥ 30%-
52 Chapter 4. Predictive factors for AUR aer HDR BT as monotherapy for low risk PCa
40% of PD is correlate with CAD due to AUR. ROC curve analysis suggested 34.2% of PD as cut-o point
supporting our previous nding.
In this dataset, another DVH parameter for bladder was statistically signicant: bladder D10≥ 50% of
PD. However, this parameter was not evaluated in small dataset and is strongly correlated with bladder D25.
erefore, only one parameter might be used in clinical practice.
e usage of large dataset and ROC curve analysis conrmed our previous results and reinforced the
association of bladder D25 and baseline Qmax with AUR.
4.4.3 Limitations
Although this study does support the denition of new dosimetric and clinical constraints, there are
nonetheless several limitations. Foremost are the inherent biases associated, such as sample bias (systematic
error due to a non-random sample of population), with any retrospective study. Another limitation is the
small sample size and few events (patients with CAD due to AUR) to evaluate. is condition could aect
the results reducing the real strength of the outcomes. Another limitation is the missing values in clinical
variables because losing information with a small population reduces the possibility to nd any association
and replacing them could bias the results. Additionally, this study is based on “planned dose” and not “deliv-
ered dose” which means we did not take into account the treatment accuracy and anatomy variation during
treatment course which is hard to do in HDR BT seing because of the short treatment time and diculties
of patients transfer with needles in the prostate during treatment.
4.5 Conclusion
Dening predictive factors for AUR as a serous grade 3 GU toxicity is important. Our results reporting a
baseline Qmax< 10 ml/s as predictive factor for AUR is helpful in selecting patients for HDR BT, and applying
an extra dosimetric constraint as we found for bladder D25 in the daily clinic could reduce the risk of AUR.
Furthermore these two parameters are important to be investigated in future studies with larger sample size.
Chapter 5
Predictive factors for late rectal bleeding
aer HDR BT as monotherapy for low risk
prostate cancer
5.1 Purpose
To evaluate clinical and dosimetric parameters related to late rectal bleeding aer high-dose rate
brachytherapy as monotherapy treatment for prostate cancer.
5.2 Materials and Methods
In this study, patients with histological conrmed prostate carcinoma (PCa), clinical stage T1b-T2b,
Nx-0, Mx-0, Gleason score≤ 7, PSA≤ 16 ng/ml and WHO performance 1status 0-2 were treated with HDR BT
monotherapy. HDR BT monotherapy was administered in four fractions of 9.5Gy with a minimum interval
of six hours within 36 hours using one implant. In contrast to chapter 4 only one group was evaluated.
5.2.1 Patients
e small group is a selection from patients treated between 2007 and 2015 (210 patients). Fieen of
210 (7.1%) developed rectal bleeding aer primary treatment for their PCa with HDR BT. ese were analysed
together with 30 other patients with grade ≤ 1 GU and GI toxicities 2. Table 5.1 shows the patient, tumour
and treatment characteristics.
1WHO performance status in Appendix C
2GU and GI toxicities classication in Appendix B
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Table 5.1: Patient, tumour and treatment characteristics.
RB no-RB
Characteristic (n= 15 patients) (n= 30 patients)
Patient and tumour
Age at implantation(y) [mean (min-max)] 69.1 (57.8-74.8) 68.9 (53.2-79.3)
Clinical Tumor Stage
T1 [n (%)] 12 (80%) 18 (60%)
T2 [n (%)] 3 (20%) 12 (40%)
Gleason sum-score
<7 [n (%)] 12 (80%) 25 (83%)
=7 [n (%)] 3 (20%) 5 (17%)
iPSA(ng/ml) [mean (min-max)] 8 (4-12) 8.5 (4.7-14.8)
Pretreatment IPSS [mean (min-max)] 8 (2-19) 5 (0-15)
Rectum Volume (cc) [mean (min-max)] 96.9 (50.6-227.8) 103.1 (62.9-197.6)
Treatment
TRUS volume (cc) [mean (min-max)] 33.1 (18-45.5) 31.6 (18.6-50)
Needles [mean (min-max)] 17 (15-21) 16 (12-23)
PTV volume [mean (min-max)] 62.3 (41.1-90.9) 49.4 (26.6-79.2)
Abbreviations: RB = patients with rectal bleeding aer treatment;
iPSA = initial prostate-specic antigen level;
IPSS = international prostate symptom score;
TRUS = transrectal ultrasound; PTV = planning target volume at treatment.
5.2.2 Organs Delineation
For all patients, organs at risk (bladder, urethra and rectum) were delineated. e rectum was divided
into cranial rectum, caudal rectum and anus. e caudal part was dened up to 1 cm to the PTV volume and
the cranial part is the cranial one from 1cm above the PTV volume until to the lower edge of sacroiliac joint.
e anus volume was dened as the last 3 cm of the rectum volume. e cranial/caudal rectum and anus
wall were dened as the internal margin from rectum of 5 mm thin. Figure 5.1 shows an example of patient
delineation.
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Figure 5.1: e delineated organs in planning CT scan and schematic representation of dierent parts of rectum. Green
contour = bladder; red contour = PTV (prostate); yellow contour = urethra; dark green contour = cranial rectum; water
green contour = caudal rectum and lilac contour = anus.
DVH and Clinical parameters selection
For all delineated structures, such as cranial, caudal, anus part and their walls, respectively, the fol-
lowing dosimetric parameters were calculated as presented in table 5.2.
Table 5.2: List of DVH parameters
Organs DVH Parameters
Cranial/cranial wall rectum Dmean, D1cc, D2cc, D10, D25, V10, V20, V30, V40
Caudal/caudal wall rectum Dmean, D1cc, D2cc, D10, D25, V10, V20, V30, V40, V75, V80, V90
Anus/anus wall Dmean, D1cc, D2cc, D10, D25, V10, V20, V30, V40
e majority of baseline clinical variables were selected as binary parameters with the median as cut-
o values: TRUS volume (40 cc), number of needles (17), PTV volume (55 cc), age (70 years), rectum volume
(85 cc), rectum diameter (35 mm), presence or absence of anticoagulants, diabetes and hypertension, mean
prostate-rectum distance (4.5 mm) and number of needles in template row 1, 1.5 and 2 (see image 1.7c).
e rectum diameter was dened as the average diameter (3 measurements: top, mid, boom) behind
the PTV volume. e prostate-rectum distance was dened as the average distance between prostate and rec-
tum. Both measurements were collected in the median prostate-sagital view of the CT-scan. ese denitions
needed small adjustments according to the anatomy by selecting the most representative measurements (see
gure 5.2 ).
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Figure 5.2: Rectum diameter and mean rectum-prostate distance: geometric denition. Le = nominal case, righ =
adjusted case; blue contour = rectum; green contour = bladder; red contour = PTV (prostate); yellow contour = urethra.
5.2.3 Statistical Analysis and Missing Values
As described in chapter 4 section 4.2.4, SPSS statistical soware was used to perform the statistical
analysis. In this study, possible associations between DVH and/or clinical parameters and late rectal bleeding
were explored using Method B (see section 4.2.4 and 4.2.5). Mann-Whitney and Chi-square test were applied
and all variables showing p-value ≤ 0.05 were aerwards tested in univariate and multivariate logistic re-
gression. Multivariate analysis was adjusted for the following confounders: age, TRUS volume, needles and
rectum volume. Others confounders are dependent of Mann-Whitney and Chi-square test and for that reason
the list of confounders might be extended. P-value ≤ 0.05 were considered statistically signicant on MVA.
Cross-validation using receiver operating characteristic (ROC) curve analysis was used to assess how well the
found parameters were predicting for rectal bleeding. e area under ROC curve (AUC) shows the capability
to distinguish no-RB patients from RB patients. is dataset does not have missing values.
5.3 Results
In this section, the results regarding all statistical analysis will be presented. First all, DVH parameters
were analysed using Mann-Whitney test. Here, only Dmean and D25 for cranial part of rectum and Dmean,
D10 and D25 for cranial wall part of rectum showed p-values ≤ 0.05. e complete outcome is in Appendix E
and summarized results are shown in tables 5.3 and 5.4.
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Table 5.3: Mann-Whitney test outcome for rectum divided in 3 regions.
DVH Parameters RB (n=15) no-RB (n=30)
Rectum Median Median p-value
Cranial Dmean (%PD) 11.90 8.90 0.028*
Cranial D1cc (% of PD) 15.39 15.35 0.665
Cranial D2cc (% of PD) 13.95 13.79 0.665
Cranial D10 (% of PD) 15.50 13.39 0.107
Cranial D25 (% of PD) 13.67 10.69 0.034*
Cranial V10-V40 (cc) - - n.s.
Caudal Dmean (% of PD) 26.63 26.53 0.886
Caudal D1cc (% of PD) 71.96 73.96 0.312
Caudal D2cc (% of PD) 64.98 67.29 0.413
Caudal D10 (% of PD) 50.55 51.32 0.427
Caudal D25 (% of PD) 34.45 34.97 0.613
Caudal V10-V40 (cc) - - n.s.
Caudal V75-V90 (cc) - - n.s.
Anus Dmean (% of PD) 14.13 14.63 0.523
Anus D1cc (% of PD) 21.61 22.13 0.754
Anus D2cc (% of PD) 19.06 19.02 0.791
Anus D10 (% of PD) 20.32 21.71 0.773
Anus D25 (% of PD) 16.32 17.77 0.700
Anus V10-V40 (cc) - - n.s.
Table 5.4: Mann-Whitney test outcome for rectum wall divided in 3 regions.
DVH Parameters RB (n=15) no-RB (n=30)
Rectum Wall Median Median p-value
Cranial Dmean (%PD) 11.79 8.48 0.010*
Cranial D1cc (% of PD) 16.13 14.45 0.132
Cranial D2cc (% of PD) 13.69 12.23 0.107
Cranial D10 (% of PD) 17.57 13.56 0.028*
Cranial D25 (% of PD) 13.61 10.03 0.011*
Cranial V10-V40 (cc) - - n.s.
Caudal Dmean (% of PD) 26.53 27.63 0.962
Caudal D1cc (% of PD) 71.96 73.98 0.324
Caudal D2cc (% of PD) 64.95 66.44 0.386
Caudal D10 (% of PD) 58.48 60.63 0.258
Caudal D25 (% of PD) 34.52 37.20 0.248
Caudal V10-V40 (cc) - - n.s.
Caudal V75-V90 (cc) - - n.s.
Anus Dmean (% of PD) 14.34 14.42 0.596
Anus D1cc (% of PD) 20.21 20.75 0.754
Anus D2cc (% of PD) 16.97 17.62 0.754
Anus D10 (% of PD) 20.47 21.82 0.700
Anus D25 (% of PD) 16.27 17.62 0.665
Anus V10-V40 (cc) - - n.s.
Abbreviations: RB = Rectal bleeding; no-RB= patients without RB;
* Statistically signicant.
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Rectum and rectum wall were also evaluated on Mann-Whitney test but taking into account the entire
volume delineated. In other words, the rectum volume and rectum wall were not divided in dierent parts.
Only rectum Dmean was statistically signicant. e outcome of this test is shown in table 5.5 and 5.6 for
rectum and rectum wall, respectively.
Table 5.5: Mann-Whitney test outcome for rectum as entire volume.
DVH Parameters RB (n=15) no-RB (n=30)
Rectum Median Median p-value
Dmean (% of PD) 22.74 20.70 0.029*
D1cc (% of PD) 72.29 74.28 0.360
D2cc (% of PD) 65.19 67.09 0.386
D5cc (% of PD) 52.15 53.20 0.754
D10 (% of PD) 43.42 42.76 0.923
D25 (% of PD) 28.27 27.24 0.283
V10 (cc) 69.01 65.60 0.773
V20 (cc) 37.30 33.52 0.656
V30 (cc) 19.19 17.74 0.885
V40 (cc) 11.03 10.16 0.942
V75 (cc) 0.71 0.92 0.289
V80 (cc) 0.23 0.43 0.373
V90 (cc) 0.00 0.02 0.489
Table 5.6: Mann-Whitney test outcome for rectum wall as entire volume.
DVH Parameters RB (n=15) no-RB (n=30)
Rectum wall Median Median p-value
Dmean (% of PD) 22.63 20.47 0.123
D1cc (% of PD) 72.04 74.10 0.312
D2cc (% of PD) 64.95 66.56 0.348
D5cc (% of PD) 41.28 45.64 0.399
D10 (% of PD) 46.34 47.36 0.700
D25 (% of PD) 26.54 25.29 0.727
V10 (cc) 36.09 34.03 0.312
V20 (cc) 17.07 16.62 0.926
V30 (cc) 9.08 9.46 0.596
V40 (cc) 5.20 6.22 0.555
V75 (cc) 0.68 0.90 0.233
V80 (cc) 0.18 0.42 0.335
V90 (cc) 0.00 0.01 0.340
Abbreviations: RB = Rectal bleeding;
no-RB= patients without RB;
* Statistically signicant.
Regarding to the clinical variables in this analysis, only PTV volume ≥ 55 cc and hypertension were
statistically correlated to rectal bleeding. e outcome of Chi-square test is shown in table 5.7. Aerwards, we
also looked for any dierence in the number of needles in dierent rows of the template between cases and
controls. In that case, Mann-Whitney test was applied and no correlation was found. is result are shown
in table 5.8.
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Table 5.7: Result of Chi-square.
RB no-RB
Clinical Parameters (n=15) (n =30) p-value
Age (years) 0.673
≥ 70 8 (53%) 14 (47%)
< 70 7 (47%) 16 (53%)
TRUS volume 0.197
≥ 35 cc 8 (53%) 10 (33%)
< 35 cc 7 (47%) 20 (67%)
Needles 0.053
≥ 17 12 (80%) 15 (38%)
< 17 3 (20%) 15 (62%)
PTV volume 0.013*
≥ 55 cc 10 (67%) 8 (27%)
< 55 cc 5 (33%) 22 (73%)
Rectum diameter 0.526
≥ 35 mm 9 (60%) 15 (50%)
< 35 mm 6 (40%) 15 (50%)
Rectum Volume 0.399
≥ 85 cc 9 (60%) 16 (53%)
< 85 cc 6 (40%) 14 (47%)
Rectum wall volume 0.180
≥ 45 cc 8 (53%) 22 (73%)
< 45 cc 7 (47%) 8 (27%)
P-R distance 0.396
≥ 4.5 mm 8 (53%) 12 (40%)
< 4.5 mm 7 (47%) 18 (60%)
Hypertension 0.034*
yes 10 (67%) 10 (33%)
no 5 (33%) 20 (67%)
Diabetes 0.101
yes 3 (20%) 1 (4%)
no 12 (80%) 29 (96%)
Use of anticoagulants 0.454
yes 4 (27%) 5 (17%)
no 11 (73%) 25 (83%)
Abbreviations:
P-R distance = prostate-rectum distance;
* Statistically signicant.
Table 5.8: Number of needles evaluation by row 1, 1.5 and 2 of the template.
RB (n=15) no-RB (n=30)
Variables Median Median p-value
Needles in row 1 2 1 0.312
Needles in row 1.5 4 4 0.454
Needles in row 2 5 4 0.167
Needles in row 1+1.5+2 10 10 0.348
Needles in row 1+1.5 6 6 0.712
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Clinical and dosimetric variables with p-values ≤ 0.05 were considered statistically signicant to in-
clude on univariate and multivariate analysis. All variables retained the statistical signicance as independent
factors. Only the OR of hypertension changed substantially aer adjustment which means that parameter is
not an independent factor associated with RB aer treatment. e results are shown in table 5.9.
Table 5.9: UVA and MVA analysis.
UVA MVAγ
Parameters OR (95%CI) p-value OR (95%CI) p-value
Rectum: Cranial part
Dmean 1.29 (1.05-1.60) 0.017 1.29 (1.05-1.60) 0.017*
D25 1.22 (1.01-1.48) 0.039 1.22 (1.01-1.48) 0.039*
Rectum Wall: Cranial part
Dmean 1.33 (1.07-1.65) 0.010 1.33 (1.07-1.65) 0.010*
D10 1.18 (1.01-1.38) 0.035 1.18 (1.01-1.38) 0.035*
D25 1.25 (1.04-1.51) 0.018 1.25 (1.04-1.51) 0.018*
Rectum (entire vol)
Dmean 1.27 (0.99-1.63) 0.059 1.27 (0.99-1.63) 0.059
PTV volume ≥ 55 cc 5.50 (1.43-21.10) 0.013 5.50 (1.43-21.10) 0.013*
Hypertension (yes) 4.00 (1.07-14.90) 0.039 7.46 (1.53-36.44) 0.013*
Abbreviations: * Statistically signicant;
UVA = univariate analysis; MVA = multivariate analysis;
OR = Odd ratio; 95% CI = 95% Condence Interval;
γ Adjusted for age, TRUS volume, needles, anticoagulants and rectum volume.
Within all parameters under investigation, only PTV volume can be tested in large dataset (210 patients
treated between 2007-2015). In this phase, we excluded from control group all patients with grade 2-3 GI
toxicity because that patients might play a role as intrinsic confounders. Dierences between cases (15 RB)
and controls (180 no-RB) in terms of PTV volume were tested using Chi-square test. In this test, PTV volume
≥ 55 cc lost the statistically signicant with p-value of 0.300 which means that there were no dierences in
terms of PTV volume between bleeders and no-bleeders in large dataset.
Aer this analysis, cross-validation was performed using ROC curve analysis. For this project work,
the optimal cut-o point for statistical signicant parameters (see table 5.9)was not explored. e reason for
that will be explained in following sections. Table 5.10 and table 5.11 show the AUC for each DVH parameter
and clinical variables, respectively. Figure 5.3 and gure 5.4 show the ROC curves. However, this method
proves the accuracy of our results. e statistically signicant variables still have a modest correlation with
rectal bleeding.
Table 5.10: AUC analyses for each statistical signicant parameter.
AUC Std.Error Asymptotic Sig. 95% CI
Cranial Dmean 0.70 0.093 0.028 0.521-0.886
Cranial D25 0.69 0.091 0.034 0.517-0.874
Cranial wall Dmean 0.74 0.088 0.010 0.567-0.911
Cranial wall D10 0.70 0.089 0.028 0.528-0.876
Cranial wall D25 0.73 0.085 0.011 0.566-0.900
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(a) ROC curves for cranial rectum. (b) ROC curves for cranial wall rectum.
Figure 5.3: ROC curves for DVH parameters of cranial/cranial wall of rectum.
Table 5.11: AUC analyses for each statistical signicant clinical parameter.
AUC Std.Error Asymptotic Sig. 95% CI Cut-o point
PTV 0.75 0.077 0.006 0.603-0.903 54 cc
PTV* 0.61 0.071 0.146 0.474-0.751 -
Hypertension 0.67 0.087 0.071 0.496-0.837 -
Notes: * large group
Figure 5.4: ROC curves for PTV volume and Hypertension.
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5.4 Discussion
To the best of our knowledge, this is the rst study to investigate predictive risk factors of rectal
bleeding aer HDR BT as monotherapy. For this study, we compared the DVH and clinical variables of 15 PCa
patients with RB with those of 30 PCa patients without RB. We found that prostate PTV volume ≥ 55 cc and
hypertension were signicantly associated with increased risk of RB. Additionally, some DVH parameters of
cranial/cranial wall part of rectum were statistically signicant. However, the clinical relevance of this result
is still unclear.
DVH Parameters
In our study, we evaluated dose to dierent parts of rectum (cranial, caudal and anus) to investigate
the possible correlation with rectal bleeding. In the MVA, we found that Dmean and D25 for cranial part of
rectum and Dmean, D10 and D25 for cranial rectum wall were statistically signicant. However, analysing
the median values for those parameters (see table 5.3-5.6), RB patients received more dose than no-RB patients
but only low dose level of 11%-18% of prescribed dose (1-1.7Gy per fraction). Cranial rectum showed huge
anatomy variations (see gure 5.2) which might explain the dierences in cranial rectum dose between RB
patients and no-RB patients. In summary, although ROC curve analysis conrmed the results with high AUC
values for cranial and cranial wall parameters, those low dose levels could not well explain the expected dose
eect relation to induce rectal bleeding.
In literature, there are several studies reporting “intermediate” doses as cause-eect of rectal bleeding
aer EBRT. Jackson et al. [50] suggested a correlation between late rectal bleeding and the volume irradiated
at an “intermediate” dose approximately of 40-50Gy. Fiorino et al. [67] found an association with grade 1-3
bleeding and larger rectum volume receiving doses of 50-60Gy (EQD23). Over the years, other studies have
conrmed that hypothesis [52, 68, 69, 70] for EBRT. However, we cannot directly compare these ndings with
our study because the treatment modality and fractionation schema is dierent. Using EQD2, the 60Gy in
EBRT can be converted roughly in 30Gy for HDR BT usingα/β(rectum) = 3Gy [9]. is value (30Gy) represents
roughly 80% of prescribed dose for HDR BT (9.5Gy in 4fr). Due to excellent dose fall-o, the 30Gy dose is
limited to < 1 cc of rectum volume in HDR BT whereas the volume receiving 60Gy in EBRT is 50/55% (' 50
cc).
LDR BT studies [56, 55, 71, 72] have been reported associations between rectal volumes receiving
higher doses (> 100% of PD) and RB. Recently, Okamoto et al. [59] investigated separately the eect of
EBRT and HDR (in combination therapy). ey suggested the estimated radiation doses delivered during
HDR BT to 5% and 10% (D5 and D10) of rectum volume in patents with late rectal bleeding were 48% (5.1Gy)
and 44% (4.6Gy) of PD (10.5Gy as boost), respectively. In our study, we did not observed dierences between
RB patients and no-RB patients in rectum dose > 18% of PD.
e DVH parameters of cranial part of rectum were statistically signicant but clinically hardly rel-
evant to be related to rectal bleeding. e small sample size and the sharp constraints followed in our HDR
protocol may gave diculties to extract dosimetric correlations.
Clinical Parameters
Clinical variables , such as rectum volume, rectum diameter, rectum wall volume, TRUS volume, total
of needles used and number of needles in row 1, 1.5 and 2 of the template, were investigated and did not reveal
any correlation with RB.
EBRT studies [50, 53, 54, 73] reported possible correlation between small rectum volume and risk of
rectum bleeding, because small volumes could receive higher concentrated dose on smaller volume disturbing
3Equivalent dose in 2Gy fractions: EQD2 = nd( d+α/β2+α/β ) ; n = number of fractions; d = dose per fraction.
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repair capacity. In our study, the mean rectum volume in patients who developed RB was smaller than in
those without bleeding (see table 5.1). Although, these results showed a slightly tendency on that inverse
relationship, the dierences was not statistically signicant. In our study, prostate-rectum distance was not
correlated with RB. In contrast, Kang et al. [74], suggested small distances between prostate and rectum
(measured in median sagial view on MRI) as predictive factor for late rectal complications aer LDR BT.
One possible reason of our results is the accuracy of the measurement by using CT-scan images comparing
with previous study where they used MRI. Other possible cause is the anatomy variance among the patients
which makes this measurement dicult to have a clear denition.
Our study also focused on the relation between RB and some specic comorbidities such as Diabetes
Mellitus (DM) and Hypertension. ese comorbidities cause damage to the microvasculature by inducing
endothelial and vascular smooth muscle dysfunction and may prevent optimal repair aer radiation acute
damage. is suggest that radiation-induced pathologic changes that will be aggravated in patients with DM
[75, 76]. However, our results did not found a correlation between DM and RB as other studies [56, 57, 70,
72, 77]. e lower reported incidence of DM in our data (4%) compared to normal population (12-20% of man
population between 60 and 80 years [78]) and the small sample size could be two limitations that prevent
representative results.
Our dataset has a representative sample (33% of no-RB patients) compared to the incidence rate of
Hypertension in Dutch man (37.4%) [79] and it was signicantly correlated with the increase risk of RB aer
HDR BT as monotherapy. However, its OR changed aer adjustment for the confounders which might be
caused by the correlation of that parameter with age. Despite this, the ROC curve analysis showed AUC =
0.67 which indicates that Hypertension predicts beer rectal bleeding than by chance. In literature, to the
extent of our knowledge, studies [59, 72] reported no correlation between Hypertension and RB. Reasons
for this is the fact that Hypertension is mostly not well reported and the lack of information on well treated
Hypertension and not treated Hypertension. In conclusion, for both Diabetes and Hypertension, it is worthy
to investigate these 2 factor in a larger data set.
In this investigation, we also assessed the link between the usage of anticoagulants and the occurrence
of RB aer HDR BT. Anticoagulation therapy is required for many patients with cardiovascular disorders and
that prolongs the time that it takes for blood to clot. Treatment with anticoagulant medications can result in
episodes of bleeding itself, and for men undergoing radiotherapy that chance is expected to be greater. Our
ndings are in accordance with those from other published studies [59, 70, 77], where they also did not nd
any correlation between taking anticoagulants and occurrence of RB. However, Harada et al. [57] found the
usage of anticoagulants as the most signicant predictive factor of RB aer LDR BT. One possible reason for
our results was that the anticoagulants were checked only at the time HDR BT started.
In our study, patients with PTV volume exceeding 55 cc have more change to develop RB aer HDR
BT as monotherapy. In addition, PTV volume is the only factor that we can test by using the entire dataset
of patients (treated between 2007 until March 2015) and PTV volume ≥ 55 cc lost its statistical signicance.
Although, ROC analysis conrmed the cut-o point for PTV volume, our results are inconclusive and suggest
that PTV volume might have a relationship with RB but because of the few patients with RB, the statistical
power is reduced.
In EBRT studies [70, 77], the investigators oen look at prostate volume before treatment and no
correlation with that variable and occurrence of RB was observed. Skwarchuk et al. [53] also investigated
PTV volume and it was not statistically signicant. LDR BT studies [58, 57, 56, 80] investigated the relationship
with RB and prostate volume based on ultrasound images but no correlation between these two parameters
was found.
In conclusion, we did not observe any reliable correlation with DVH parameters or PTV volume and
RB. Hypertension was the most signicant factor associated to RB but it cannot be considered as predictive
factor.
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Limitations
is study does not support the denition of new clinical or dosimetric constraints but there are
nonetheless limitations. First of all, in this study, like in other retrospective studies, there are inherent biases.
As discussed in the previous chapter, the few events (patients who developed RB) compromise the statistical
power of these results. Additionally, this study is based on “planned dose” and not “delivered dose” which
means we did not take into account the treatment accuracy and anatomy variation during treatment course.
However, this study is an important tool for new investigations because it gives indication in what we should
look at in future researching.
5.5 Conclusion
In our study, either in terms of DVH parameters or clinical variables, the results are inconclusive. In the
cranial rectum, some DVH parameters were statistically correlated with RB but without clinical relevance. e
PTV volume did not show clear relationship when tested in the large dataset. Hypertension was statistically
associated with RB. However, the number of events is small and thus the power of these observations is limited
and requires conrmation in a larger cohort of patients with RB. In conclusion, this study is an interesting
guideline for future investigations in this area.
Chapter 6
Discussion and conclusions
6.1 Summary of esis
Fractionated HDR BT is being increasingly used for low/intermediate PCa. is treatment modality
oers direct delivering of high doses to the prostate while sparing the normal surrounding tissue, in particular,
bladder and rectum. is makes HDR BT one of the most ecient and eective technique to treat organ
confound PCa in few large fractions. However, there are some side eects, such as: AUR and RB. erefore, the
main objective of this thesis was to investigate clinical and dosimetric parameters related to those secondary
eects aer HDR BT as monotherapy. is thesis is separated in the following chapters:
• Introduction of HDR BT modality: Physical aspects up to clinical procedure and side eects (chapter 1);
• General statistical procedures in this research area (chapter 2);
• Bibliography review about the technique itself and their outcomes in terms of toxicities (chapter 3);
• Risk factors for AUR and RB (chapter 4 and 5, respectively).
6.2 General Discussion
EBRT and LDR treatments are the well-known treatment modalities for PCa and there are several
studies that investigated the causes of side eects, such as: AUR and RB. Nowadays, the sources of that side
eects are well-known for EBRT/LDR BT. However, HDR BT as monotherapy is a relatively recent technique
and further investigation is required to understand and establish the secondary eects. erefore, to the best
of our knowledge, our study is the rst study investigating the predictive factors of AUR and RB for HDR
monotherapy.
Although GU and GI toxicities rates aer HDR BT are generally low, AUR and RB are well-established
potential toxicities. ese side eects, although oen transient, cause a great deal of anxiety and discomfort
eecting the patient’s quality of life. ese complications are also an issue for physicians and medical physi-
cists because they want to minimize as much as possible those side eects. erefore, this study added new
information about what we can do to improve the daily routine of those patients aer treatment.
Clinical and Dosimetric Data
In these investigations, clinical and dosimetric information are oen used to assess to the factor that
rises the chance of development a certain side eect. Dosimetric data is collected from treatment planning
soware’s which means we use “planned doses” and not “delivered doses”.
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erefore, one interesting eld to discuss is the treatment accuracy. e uncertainties during brachy-
therapy treatments and their occurrence rates are not well known and it becomes crucial for patients with
target and/or OAR doses closes to constraint values. In addition, the high dose gradient in HDR BT makes the
treatment delivery challenging and since even small geometric/dosimetric uncertainties may result in large
dose discrepancies from the original plan.
First of all, our results are based on the planning CT assuming neither needles displacements nor organ
movements. is HDR BT treatment is administrated in four fractions of 9.5Gy with a minimum interval of 6h
within 36h. Because of short treatment time per fraction (≈ 10-15 minutes) we do not expect large dierences
in anatomy/organ motion. However, there are natural displacements of needles in caudal direction and this
eect was already studied [81]. erefore, in ErasmusMC - Cancer Institute, a lateral x-ray is made before each
fraction to check the position of the tip of the catheters relative to the markers. Displacements exceeding
3mm are corrected by pushing the catheters to the planned depth as indicated by their position relative to the
markers. In our study was not possible to include this factor in analysis and there is no way to know exactly
how accurate the treatment was. ere are always some accuracies, such as organ motion, source positioning,
contouring or dose delivery, which are not quantied. Furthermore, BT treatments are not monitored with
independent control systems from the delivery unit that make the possibility of that uncertainties remain
undetected during the entire treatment course.
Regarding to clinical data, we can split that up into two domains: data reported by patient (question-
naires, e.g. IPSS score) or medical information reported by physicians (medical examination, e.g. Qmax or
urinary residue). Periodically, in ErasmusMC - Cancer Institute, questionnaires are sent to the patients. It is
an easy tool to assess the patient’s qualify of life in several domains (e.g. urinary function or sexual function)
before and aer treatment. e usage of questionnaires allows to assess the toxicity not only reported by the
physician but also by the patients improving the report of toxicities [13]. It also allows to analyse the toxicity
behaviour in function of time.
On the other hand, clinical data (patient and medical information) has some problems associated. It is
oen not very well recorded resulting in incomplete data. erefore, another big issue is the missing values.
When we try to analyse clinical variables, sometimes those parameters are not lled in causing troubles in
performing statistical analysis. First, the majority of statistical soware excludes the patient if it nds one
missing value in one parameter. is technique has some limitations, mainly, reducing the sample size and
the variability. Second, there are some techniques to replace those missing values by estimated measures
using simple or complex techniques: Mean/Median replacements or Multiple Imputation. However, those
techniques calculate the values based on data available which might boost the presence of some relationship
providing an overestimation of results. Consequently, when we analyse clinical variables it is important to
have a large sample to cover the eect of missing values. In chapter 2, some techniques to replace missing
values were shown. ose methods were evaluated and their results are shown in chapter 4. Because of this
problem, Qmax, one of the most important risk factor for AUR according our results, has a modest statistical
power.
Sample Size and Methodology
is study provides new clinical and dosimetric parameters but it is important to discuss the validity
of these results. First of all, this study is limited by the number of events (patients who developed AUR or RB)
which makes the statistical analysis less powerful. e incidence of each side eect is small in total of patients
treated, in other words, we always have far more controls than cases to include in the analysis. erefore,
including more patients is in one side (controls) only. e question is: Will it boost the statistical analysis?
Rik Bijman, master student in ErasmusMC - Cancer Institute, developed NTCP models for each symp-
tom of late GU and GI toxicities aer EBRT for prostate cancer [82]. He modelled NTCP 1 models based on
1NTCP: Normal tissue complication probability.
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clinical and DVH parameters of 800 patients (HYPRO study 2) and he concluded that even with a large amount
of patients it is hard to model certain symptoms. Again, the main reason is that the number of cases for each
side eect is not well distributed among the number of patients treated. erefore, one of the questions is:
What is the ideal number of patients to analyse?. If we have a small sample size, the results will be based on
one part of the entire population. However, if we have a large sample simple, we will have large variety which
will introduce noise that might mask some relationship. In conclusion, the main issue in this kind of study is
not the sample size but it is the number of cases versus controls.
In our study, we used two dierent methods to analyse the data: Method A and Method B. As discussed
in chapter 4, to apply multivariate logistic regression, 1 covariate per 10 events is required. Our data study
does not allow to perform multivariate logistic regression and in that case we tested Method B. We believe
that Method B is suitable in case of datasets with small percentage of cases versus controls resulting in more
powerful outcomes. Even though, the results are always limited by small events in this dataset. Despite this,
it is always important prevent side eects that cause a great discomfort and change the daily routine of the
patients even when their incidence rate is low.
Clinical Relevance and Applicability of Results
In chapter 4 and 5, it was shown that there are some important parameters which might be correlated
with AUR and RB. Patients with Qmax before treatment lower than 10 ml/s have higher risk of AUR and it
will be useful in selecting patients for HDR BT.
When patients already have bad urinary condition before treatment, one common procedure is the
prescription of medicaments which prevent and improve urinary retention, such as α-blockers or corticos-
teroids. is eect is very well illustrated by prospective randomized trial [83] where they evaluated in a
total of 234 patients, 142 patients who received an α-blocker 1 week prior to treatment versus the remaining
patients who did not take it. Only 1.5% of patients who took these medication and 4% of patients who did
not had urinary retention. erefore, Qmax provides additional information and might help in prescription
of that medication before treatment.
One of the big issues in radiotherapy is always the balance between acceptable PTV coverage and
sparing OAR. We never optimize both sides, if we want to increase, for instance, PTV coverage from 95%
to 99% of PD, we always will deliver more dose in OAR. First of all, this is the rst study reporting DVH
parameters as risk factors of AUR which means more studies will be necessary to prove this relationship. Even
more, the patient will benet if the side eects can be minimized, but it might reduce the tumour control rate.
erefore, our study suggests that we should pay aention to those parameters and try to minimize them
without degrading PTV coverage. One of the next steps is to simulate the eect of adding those parameters
in treatment constraints and evaluating how much the PTV coverage is aected – planning study. is is the
simplest way to evaluate how much the dose distribution will be changed.
In conclusion, in this kind of studies it is always important when we nd new predictors but even
more meaningful is to understand how we can use that in clinical point-of-view.
6.3 General Conclusion
e risk factors of acute urinary retention and rectal bleeding are likely multifactorial in nature and
we only evaluated those side eects by using the available candidates to be a risk factors. For that reason,
further research in dierent cancer institutes might lead to an extension and improvement of the predictive
variables for those secondary eects. In conclusion, although this study has some limitations, it provides the
rst predictive factors for AUR.
2Randomized controlled trial for intermediate and high risk Prostate cancer patient treated in two arms: 39 x 2Gy and hypofrac-
tionated scheme 19 x 3,4Gy; 7 participating Dutch radiotherapy departments.
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6.4 Future Perspectives
In this section I will provide the most recent developments and areas of interest in HDR brachytherapy.
6.4.1 Single fraction HDR BT
In ErasmusMC - Cancer Institute (Roerdam, e Netherlands) a study to treat patients with HDR BT
in one fraction is being developed. Hypofractionation regimens with curative intend of prostate cancer have
been shown good results, specially, HDR BT delivered in 4 fractions over short period of time [13]. Applying
HDR BT in one fraction will improve patient comfort during treatment, improve treatment accuracy excluding
needles displacements correction and save time, costs and human resources.
One of the main research groups in brachytherapy and more recently in HDR BT in one fraction,
Hoskin et al. [84], published in 2014 one study about early urinary and gastroinstestinal adverse events
aer two or one fraction of HDR BT. eir study suggested that single dose HDR BT delivering 19Gy or 20Gy
is associated with higher rates of acute toxicity than seen with two-fraction schedule. ey also observed
a signicant increase in catheter use in the rst 12 weeks aer implant of 19Gy or 20Gy compared with 2 x
13Gy. Single fraction HDR BT always has an argument of that single dose is less traumatic with the implant in
place for only a few hours compared to 24h for two fraction or 36h for 4 fractions schedule. erefore, single
dose HDR BT remains an aractive treatment possibility with an acceptable level of acute complications.
However, it is not clear yet what is the best dose level and the search for the optimal HDR BT schedule for
prostate cancer remains a challenge.
Recently, in 2016, one research group from Spain published their study [85] where they evaluated
acute and late genitourinary, gastrointestinal toxicity and the long-term biochemical control aer HDR BT
monotherapy in one fraction (19Gy). No severe toxicities were reported and overall survival was 90% (± 5%)
and biochemical control was 66% (± 6%) at 6 years . erefore, they concluded that single fraction schedule
(19Gy) is feasible and well tolerated but not with the same level of LDR biochemical control at 6 years.
In conclusion, this modality of HDR BT seems to be a promising schedule and our study about risk
factor for CAD due to AUR might be helpful for those studies.
6.4.2 Brachytherapy uncertainties and in vivo dosimetry (based on [1, 86, 87])
One of the most challenging areas in brachytherapy is related to how to measure and take into account
the uncertainties during BT treatment. is is the eld that still have lot of research work to do. HDR BT is
known to have high dose gradients that makes accurate dose measurements and treatment delivery challen-
ging because even small uncertainties may result in large dose discrepancies. erefore, the main problem is
that uncertainties can remain undetectable because those systems do not use independent tools to monitor
that.
BT uncertainties come from treatment planning, imaging, anatomical variations and dose delivery. It
is essential to identify these uncertainties, their magnitude and their impact on the overall uncertainty of dose
delivery to the patients. One example of treatment planning uncertainties is that treatment planning system
(TPS) incorporate AAPM Task Group No.43 dose calculation protocol [6]. is assumes that patient is made
of water and neglects tissue heterogeneities introducing uncertainties in dose calculation.
Imaging uncertainties are related to organs contouring (user’s dependency) and also addressed to
computational limitations and assumptions due to the nite slice thickness. Anatomical variation in HDR
BT is not a big issue because the treatment delivery time is short. However, for LDR BT, the target volume
changes substantially during the time of relevant dose delivery and that is not taken into account in dose
calculations. Another source of uncertainty is the post-implant oedema that might overestimate the total
dose administered. Dose delivery accuracy depends on the consistency of the patients and delivery geometry
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between treatment planning and treatment delivery. Systematic eects of aerloader accuracy is veried and
checked by the system itself and it is possible to calibrate and eliminate those discrepancies. However, the
precision of the source positioning during treatment remains to be quantied. A new eld in brachytherapy
will add a signicant improvement in this domain named in vivo dosimetry (IVD).
Initially, in vivo dosimetry was used only to verify dose delivered to the OARs and tumour, namely in
techniques administering large dose per fraction as HDR BT, placing the dosimeter inside patients. Nowadays,
IVD may be also a tool to detect needles/catheter displacements and organ motions between fractions. Over
the years, detectors and sensors have been developed in order to improve the in vivo dosimetry but physical
and mechanical problems, such as energy or temperature dependence, have been precluded that usage in
clinical practice. e implementation of this systems is used mostly in research and development because
it might introduce potential risk and discomfort to the patient as well as extra human eort and potential
interference with the existing clinical workow. erefore, in vivo dosimetry is a promising research area in
brachytherapy and it still have lot of research to do because there is a lack of good infrastructure in terms of
commercially available dosimetry systems with straightforward procedures.
For interested reader in in vivo dosimetry and BT uncertainties, we recommend Kertzscher et al.
[86], Tanderup et al.[88] and Kirisits et al. [87]. In conclusion, it is important to understand the sources of
BT uncertainties and to quantify them in order to improve the outcome in terms of local control and beer
OAR sparing.
Appendix A
UICC TNM Classication of Prostate Tumors (2009)
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Appendix B
Adapted RTOG/EORTC Late Radiation Morbidity
Scoring
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Appendix C
WHO performance status classication
Grade Explanation of activity
0 Fully active, able to carry on all pre-disease performance without restriction
1 Restricted in physically strenuous activity but ambulatory and able to carry outwork of a light or sedentary nature, e.g., light house work, oce work
2 Ambulatory and capable of all selfcare but unable to carry out any work activities.Up and about more than 50% of waking hours
3 Capable of only limited selfcare, conned to bed or chair more than 50% of waking hours
4 Completely disabled. Cannot carry on any selfcare. Totally conned to bed or chair
5 Dead
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Appendix D
Complete results of Chapter 4: Method A - Small
Group
Table D.1: Completed Result of TEST.A1.
Original Data : TEST.A1
Univariate
Variable p-value OR (95%CI)
Bladder D1cc 0.144* 1.09 (0.97-1.22)
Bladder D2cc 0.098* 1.11 (0.98-1.27)
Bladder D25 0.005* 1.25 (1.07-1.45)
Bladder V75 0.018* 3.36 (1.23-9.19)
Bladder V80 0.034* 4.99 (1.13-22.03)
Bladder V75 (cc) 0.260 -
Bladder V80 (cc) 0.371 -
Bladder Neck D0.1cc 0.747 -
Bladder Neck D0.5cc 0.163* 1.10 (0.96-1.27)
Bladder Neck V80 0.450 -
Bladder Neck V80 (cc) 0.718 -
PUS D0.1cc 0.284 -
PUS D30 0.647 -
PUS V110 0.434 -
PUS V110 (cc) 0.441 -
PUM D0.1cc 0.250 -
PUM D30 0.299 -
PUM V110 0.962 -
PUM (cc) 0.079 71.37 (0.61-8354.10)
PUI D0.1cc 0.363 -
PUI D30 0.645 -
PUI V110 0.745 -
PUI V110 (cc) 0.371 -
UM D0.1cc 0.622 -
UM D0.5cc 0.043* 1.09 (1.00-1.18)
UM D30 0.309 -
UM V100 0.063 1.21 (0.99-1.47)
UM V100 (cc) 0.119* 1.9E+8 (0.008-4.6E+18)
TRUS volume ≥ 40 cc 0.036* 4.60 (1.11-19.14)
Qmax < 15 ml/s 0.096* 3.61 (0.79-16.35)
Urinary residue ≥ 30 ml 0.910 -
IPSS ≥ 10 0.121* 3.33 (0.72-15.26)
Needles ≥ 17 0.084* 3.67 (0.83-16.04)
PTV Volume ≥ 50 cc 0.132* 2.89 (0.73-11.43)
Urethra length ≥ 50 mm 0.509 -
Age ≥ 70 year 0.663 -
Abbreviations: * Statistically signicant (p-value ≤ 0.2);
PUS = Prostatic Urethra Superior; PUM = Prostatic Urethra MID;
PUI = Prostatic Urethra Inferior; UM = Membranous Urethra;
OR = Odd ratio; 95% CI = 95 % Condence Interval.
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Table D.2: Completed Result of TEST.A3.
Univariate Multivariate
Variable p-value p-value OR (95%CI)
Bladder D1cc 0.144* 0.677 -
Bladder D2cc 0.098* 0.691 -
Bladder D25 0.005* 0.006** 1.32 (1.08-1.60)
Bladder V75 0.018* 0.768 -
Bladder V80 0.034* 0.807 -
Bladder V75 (cc) 0.260 - -
Bladder V80 (cc) 0.371 - -
Bladder Neck D0.1cc 0.747 - -
Bladder Neck V80 0.450 - -
Bladder Neck V80 (cc) 0.718 - -
PUS D0.1cc 0.284 - -
PUS D30 0.647 - -
PUS V110 0.434 - -
PUS V110 (cc) 0.441 - -
PUM D0.1cc 0.250 - -
PUM D30 0.299 - -
PUM V110 0.962 - -
PUM V110(cc) 0.079* 0.351 -
PUI D0.1cc 0.363 - -
PUI D30 0.645 - -
PUI V110 0.745 - -
PUI V110 (cc) 0.371 - -
UM D0.1cc 0.622 - -
UM D0.5cc 0.043 0.333 -
UM D30 0.309 - -
UM V100 0.063* 0.104 -
UM V100 (cc) 0.119* 0.515 -
TRUS volume ≥ 40 cc 0.036* 0.667 -
Qmax < 15 ml/s 0.036* 0.039** 39.82 (1.19 -1325.86)
Urinary residue ≥ 30 ml 0.827 - -
IPSS ≥ 10 0.121* 0.021** 74.11 (1.91-2879.46)
Needles ≥ 17 0.084* 0.104 -
PTV Volume ≥ 50 cc 0.132* 0.323 -
Urethra length ≥ 50 mm 0.509 - -
Age ≥ 70 year 0.663 - -
* Statistically signicant (p-value <0.2): Pre-selection;
**Statistically signicant (p-value ≤0.05);
PUS = Prostatic Urethra Superior; PUM = Prostatic Urethra MID;
PUI = Prostatic Urethra Inferior; UM = Membranous Urethra;
OR = Odd ratio; 95% CI = 95% Condence interval.
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Table D.3: Completed Result of TEST.A4.
Univariate Multivariate
Variable p-value p-value OR (95%CI)
Bladder D1cc 0.144* 0.427 -
Bladder D2cc 0.098* 0.362 -
Bladder D25 0.005* 0.006 1.34 (1.09-1.66)
Bladder V75 0.018* 0.702 -
Bladder V80 0.034* 0.780 -
Bladder V75 (cc) 0.260 - -
Bladder V80 (cc) 0.371 - -
Bladder Neck D0.1cc 0.747 - -
Bladder Neck V80 0.450 - -
Bladder Neck V80 (cc) 0.718 - -
PUS D0.1cc 0.284 - -
PUS D30 0.647 - -
PUS V110 0.434 - -
PUS V110 (cc) 0.441 - -
PUM D0.1cc 0.250 - -
PUM D30 0.299 - -
PUM V110 0.962 - -
PUM V110 (cc) 0.079* 0.105 -
PUI D0.1cc 0.363 - -
PUI D30 0.645 - -
PUI V110 0.745 - -
PUi V110 (cc) 0.371 - -
UM D0.1cc 0.622 - -
UM D0.5cc 0.043* 0.336 -
UM D30 0.309 - -
UM V100 0.063* 0.217 -
UM V100(cc) 0.119* 0.264 -
TRUS volume ≥ 40 cc 0.036* 0.221 -
Qmax < 10 ml/s 0.025* 0.020** 10.08 (1.44-70.54)
Urinary residue ≥ 30 ml 0.827 - -
IPSS ≥ 10 0.121* 0.021** 16.73 (1.53-183.29)
Needles ≥ 17 0.084* 0.209 -
PTV Volume ≥ 50 cc 0.132* 0.624 -
Urethra length ≥ 50 mm 0.509 - -
Age ≥ 70 year 0.663 - -
* Statistically signicant (p-value <0.2): Pre-selection;
**Statistically signicant (p-value ≤0.05);
PUS = Prostatic Urethra Superior; PUM = Prostatic Urethra MID;
PUI = Prostatic Urethra Inferior; UM = Membranous Urethra;
OR = Odd ratio; 95% CI = 95% Condence interval.
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Table D.4: Completed Result of TEST.A6.
Univariate Multivariate
Variable p-value p-value OR (95%CI)
Bladder D1cc 0.144* 0.479 -
Bladder D2cc 0.098* 0.412 -
Bladder D25 0.005* 0.006** 1.33 (1.08-1.63)
Bladder V75 0.018* 0.674 -
Bladder V80 0.034* 0.759 -
Bladder V75 (cc) 0.260 - -
Bladder V80 (cc) 0.371 - -
Bladder Neck D0.1cc 0.747 - -
Bladder Neck V80 0.450 - -
Bladder Neck V80 (cc) 0.718 - -
PUS D0.1cc 0.284 - -
PUS D30 0.647 - -
PUS V110 0.434 - -
PUS V110 (cc) 0.441 - -
PUM D0.1cc 0.250 - -
PUM D30 0.299 - -
PUM V110 0.962 - -
PUM V110(cc) 0.079* 0.164 -
PUI D0.1cc 0.363 - -
PUI D30 0.645 - -
PUI V110 0.745 - -
PUI V110 (cc) 0.371 - -
UM D0.1cc 0.622 - -
UM D0.5cc 0.043* 0.360 -
UM D30 0.309 - -
UM V100 0.063* 0.218 -
UM (cc) 0.119* 0.259 -
TRUS volume ≥ 40 cc 0.036* 0.259 -
Qmax < 10 ml/s 0.025* 0.071 -
Urinary residue ≥ 30 ml 0.827 - -
IPSS ≥ 10 0.121* 0.044** 19.12 (1.08-338.00)
Needles ≥ 17 0.084* 0.288 -
PTV Volume ≥ 50 cc 0.132* 0.820 -
Urethra length ≥ 50 mm 0.509 - -
Age ≥ 70 year 0.663 - -
* Statistically signicant (p-value <0.2): Pre-selection;
**Statistically signicant (p-value ≤0.05);
PUS = Prostatic Urethra Superior; PUM = Prostatic Urethra MID;
PUI = Prostatic Urethra Inferior; UM = Membranous Urethra;
OR = Odd ratio; 95% CI = 95% Condence interval.
77
Table D.5: Completed Result of TEST.A7.
Univariate Multivariate
Variable p-value p-value OR (95%CI)
Bladder D1cc 0.144* 0.611 -
Bladder D2cc 0.098* 0.626 -
Bladder D25 0.005* 0.008** 1.31 (1.07-1.60)
Bladder V75 0.018* 0.697 -
Bladder V80 0.034* 0.770 -
Bladder V75 (cc) 0.260 - -
Bladder V80 (cc) 0.371 - -
Bladder Neck D0.1cc 0.747 - -
Bladder Neck V80 0.450 - -
Bladder Neck V80 (cc) 0.718 - -
PUS D0.1cc 0.284 - -
PUS D30 0.647 - -
PUS V110 0.434 - -
PUS V110 (cc) 0.441 - -
PUM D0.1cc 0.250 - -
PUM D30 0.299 - -
PUM V110 0.962 - -
PUM V110 (cc) 0.079* 0.210 -
PUI D0.1cc 0.363 - -
PUI D30 0.645 - -
PUI V110 0.745 - -
PUI V110 (cc) 0.371 - -
UM D0.1cc 0.622 - -
UM D0.5cc 0.043 0.606 -
UM D30 0.309 - -
UM V100 0.063* 0.165 -
UM V100 (cc) 0.119* 0.833 -
TRUS volume ≥ 40 cc 0.036* 0.624 -
Qmax < 15 ml/s 0.125* 0.113 -
Urinary residue ≥ 30 ml 0.827 - -
IPSS ≥ 10 0.121* 0.029** 15.76 (1.36-186.05)
Needles ≥ 17 0.084* 0.081 -
PTV Volume ≥ 50 cc 0.132* 0.427 -
Urethra length ≥ 50 mm 0.509 - -
Age ≥ 70 year 0.663 - -
* Statistically signicant (p-value <0.2): Pre-selection;
**Statistically signicant (p-value ≤0.05);
PUS = Prostatic Urethra Superior; PUM = Prostatic Urethra MID;
PUI = Prostatic Urethra Inferior; UM = Membranous Urethra;
OR = Odd ratio; 95% CI = 95% Condence interval.
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Table D.6: Completed Result of TEST.A8.
Univariate Multivariate
Variable p-value p-value OR (95%CI)
Bladder D1cc 0.144* 0.419 -
Bladder D2cc 0.098* 0.333 -
Bladder D25 0.005* 0.007** 1.31 (1.08-1.59)
Bladder V75 0.018* 0.736 -
Bladder V80 0.034* 0.807 -
Bladder V75 (cc) 0.260 - -
Bladder V80 (cc) 0.371 - -
Bladder Neck D0.1cc 0.747 - -
Bladder Neck V80 0.450 - -
Bladder Neck V80 (cc) 0.718 - -
PUS D0.1cc 0.284 - -
PUS D30 0.647 - -
PUS V110 0.434 - -
PUS V110 (cc) 0.441 - -
PUM D0.1cc 0.250 - -
PUM D30 0.299 - -
PUM V110 0.962 - -
PUM V110(cc) 0.079* 0.092 -
PUI D0.1cc 0.363 - -
PUI D30 0.645 - -
PUI V110 0.745 - -
PUI V110 (cc) 0.371 - -
UM D0.1cc 0.622 - -
UM D0.5cc 0.043* 0.265 -
UM D30 0.309 - -
UM V100 0.063* 0.211 -
UM V100 (cc) 0.119* 0.246 -
TRUS volume ≥ 40 cc 0.036* 0.131 -
Qmax < 10 ml/s 0.066* 0.044** 6.84 (1.05-44.45)
Urinary residue ≥ 30 ml 0.827 - -
IPSS ≥ 10 0.121* 0.019** 18.34(1.60-209.99)
Needles ≥ 17 0.084* 0.134 -
PTV Volume ≥ 50 cc 0.132* 0.444 -
Urethra length ≥ 50 mm 0.509 - -
Age ≥ 70 year 0.663 - -
* Statistically signicant (p-value <0.2): Pre-selection;
**Statistically signicant (p-value ≤0.05);
PUS = Prostatic Urethra Superior; PUM = Prostatic Urethra MID;
PUI = Prostatic Urethra Inferior; UM = Membranous Urethra;
OR = Odd ratio; 95% CI = 95% Condence interval.
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Table D.7: Completed Result of TEST.A9.
Univariable Multivariable
Variable p-value p-value OR (95% CI)
Bladder D1cc 0.144* 0.737 -
Bladder D2cc 0.098* 0.855 -
Bladder D25 ≥ 30% PD 0.023* 0.148 -
Bladder V75 0.018* 0.022** 5.61 (1.29-24.41)
Bladder V80 0.034* 0.199 -
Bladder V75 (cc) 0.260 - -
Bladder V80 (cc) 0.371 - -
Bladder Neck D0.1cc 0.747 - -
Bladder Neck V80 0.450 - -
Bladder Neck V80 (cc) 0.718 - -
PUS D0.1cc 0.284 - -
PUS D30 0.647 - -
PUS V110 0.434 - -
PUS V110 (cc) 0.441 - -
PUM D0.1cc 0.250 - -
PUM D30 0.299 - -
PUM V110 0.962 - -
PUM V110 (cc) 0.079* 0.056 -
PUI D0.1cc 0.363 - -
PUI D30 0.645 - -
PUI V110 0.745 - -
PUI V110 (cc) 0.371 - -
UM D0.1cc 0.622 - -
UM D0.5cc 0.043* 0.266 -
UM D30 0.309 - -
UM V100 0.063* 0.163 -
UM V100 (cc) 0.119* 0.225 -
TRUS volume ≥ 40 cc 0.036* 0.103 -
Qmax < 10 ml/s 0.066* 0.027** 8.44 (1.27-56.23)
Urinary residue ≥ 30 ml 0.827 - -
IPSS ≥ 10 0.121* 0.026** 13.59 (1.37-134.76)
Needles ≥ 17 0.084* 0.152 -
PTV Volume ≥ 50 cc 0.132* 0.604 -
Urethra length ≥ 50 mm 0.509 - -
Age ≥ 70 year 0.663 - -
* Statistically signicant (p-value <0.2): Pre-selection;
**Statistically signicant (p-value ≤0.05);
PUS = Prostatic Urethra Superior; PUM = Prostatic Urethra MID;
PUI = Prostatic Urethra Inferior; UM = Membranous Urethra;
OR = Odd ratio; 95% CI = 95% Condence interval.
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Table D.8: Completed Result of TEST.A10.
Univariable Multivariable
Variable p-value p-value OR (95% CI)
Bladder D1cc 0.144* 0.264 -
Bladder D2cc 0.098* 0.275 -
Bladder D25 ≥ 30% PD 0.023* 0.031** 26.73 (1.35-529.48)
Bladder V75 0.018* 0.321 -
Bladder V80 0.034* 0.438 -
Bladder V75 (cc) 0.260 - -
Bladder V80 (cc) 0.371 - -
Bladder Neck D0.1cc 0.747 - -
Bladder Neck V80 0.450 - -
Bladder Neck V80 (cc) 0.718 - -
PUS D0.1cc 0.284 - -
PUS D30 0.647 - -
PUS V110 0.434 - -
PUS V110 (cc) 0.441 - -
PUM D0.1cc 0.250 - -
PUM D30 0.299 - -
PUM V110 0.962 - -
PUM V110 (cc) 0.079* 0.050 -
PUI D0.1cc 0.363 - -
PUI D30 0.645 - -
PUI V110 0.745 - -
PUI V110 (cc) 0.371 - -
UM D0.1cc 0.622 - -
UM D0.5cc 0.043 0.675 -
UM D30 0.309 - -
UM V100 0.063* 0.141 -
UM V100 (cc) 0.119* 0.374 -
TRUS volume ≥ 40 cc 0.036* 0.561 -
Qmax < 10 ml/s 0.066* 0.023** 13.14 (1.43-120.85)
Urinary residue ≥ 30 ml 0.827 - -
IPSS ≥ 10 0.121* 0.013** 53.48 (2.35-1217.46)
Needles ≥ 17 0.084* 0.191 -
PTV Volume ≥ 50 cc 0.132* 0.870 -
Urethra length ≥ 50 mm 0.509 - -
Age ≥ 70 year 0.663 - -
* Statistically signicant (p-value <0.2): Pre-selection;
**Statistically signicant (p-value ≤0.05);
PUS = Prostatic Urethra Superior; PUM = Prostatic Urethra MID;
PUI = Prostatic Urethra Inferior; UM = Membranous Urethra;
OR = Odd ratio; 95% CI = 95% Condence interval.
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Table D.9: Completed Result of TEST.A11.
Univariable Multivariable
Variable p-value p-value OR (95% CI)
Bladder D1cc 0.144* 0.279 -
Bladder D2cc 0.098* 0.284 -
Bladder D25 ≥ 30% PD 0.023* 0.029** 20.26 (1.36-301.85)
Bladder V75 0.018* 0.289 -
Bladder V80 0.034* 0.419 -
Bladder V75 (cc) 0.260 - -
Bladder V80 (cc) 0.371 - -
Bladder Neck D0.1cc 0.747 - -
Bladder Neck V80 0.450 - -
Bladder Neck V80 (cc) 0.718 - -
PUS D0.1cc 0.284 - -
PUS D30 0.647 - -
PUS V110 0.434 - -
PUS V110 (cc) 0.441 - -
PUM D0.1cc 0.250 - -
PUM D30 0.299 - -
PUM V110 0.962 - -
PUM V110 (cc) 0.079* 0.050 -
PUI D0.1cc 0.363 - -
PUI D30 0.645 - -
PUI V110 0.745 - -
PUI V110 (cc) 0.371 - -
UM D0.1cc 0.622 - -
UM D0.5cc 0.043* 0.978 -
UM D30 0.309 - -
UM V100 0.063* 0.129 -
UM V100 (cc) 0.119* 0.858 -
TRUS volume ≥ 40 cc 0.036 0.882 -
Qmax < 15 ml/s 0.125* 0.169 -
Urinary residue ≥ 30 ml 0.827 - -
IPSS ≥ 10 0.121* 0.028** 32.98 (1.46-744.56)
Needles ≥ 17 0.084* 0.090 -
PTV Volume ≥ 50 cc 0.132* 0.790 -
Urethra length ≥ 50 mm 0.509 - -
Age ≥ 70 year 0.663 - -
* Statistically signicant (p-value <0.2): Pre-selection;
**Statistically signicant (p-value ≤0.05);
PUS = Prostatic Urethra Superior; PUM = Prostatic Urethra MID;
PUI = Prostatic Urethra Inferior; UM = Membranous Urethra;
OR = Odd ratio; 95% CI = 95% Condence interval.
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Table D.10: Completed Result of TEST.A12.
Univariable Multivariable
Variable p-value p-value OR (95% CI)
Bladder D1cc 0.144* 0.894 -
Bladder D2cc 0.098* 0.953 -
Bladder D25 ≥ 30% PD 0.023* 0.364 -
Bladder V75 0.018* 0.021** 5.03 (1.28-19.77)
Bladder V80 0.034* 0.296 -
Bladder V75 (cc) 0.260 - -
Bladder V80 (cc) 0.371 - -
Bladder Neck D0.1cc 0.747 - -
Bladder Neck V80 0.450 - -
Bladder Neck V80 (cc) 0.718 - -
PUS D0.1cc 0.284 - -
PUS D30 0.647 - -
PUS V110 0.434 - -
PUS V110 (cc) 0.441 - -
PUM D0.1cc 0.250 - -
PUM D30 0.299 - -
PUM V110 0.962 - -
PUM V110 (cc) 0.079* 0.112 -
PUI D0.1cc 0.363 - -
PUI D30 0.645 - -
PUI V110 0.745 - -
PUI V110 (cc) 0.371 - -
UM D0.1cc 0.622 - -
UM D0.5cc 0.043* 0.730 -
UM D30 0.309 - -
UM V100 0.063* 0.210 -
UM V100 (cc) 0.119* 0.467 -
TRUS volume ≥ 40 cc 0.036* 0.284 -
Qmax < 15 ml/s 0.036* 0.044** 23.35 (1.09-501.17)
Urinary residue ≥ 30 ml 0.827 - -
IPSS ≥ 10 0.121* 0.063 -
Needles ≥ 17 0.084* 0.137 -
PTV Volume ≥ 50 cc 0.132* 0.854 -
Urethra length ≥ 50 mm 0.509 - -
Age ≥ 70 year 0.663 - -
* Statistically signicant (p-value <0.2): Pre-selection;
**Statistically signicant (p-value ≤0.05);
PUS = Prostatic Urethra Superior; PUM = Prostatic Urethra MID;
PUI = Prostatic Urethra Inferior; UM = Membranous Urethra;
OR = Odd ratio; 95% CI = 95% Condence interval.
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Table D.11: Completed Result of TEST.A13.
Univariable Multivariable
Variable p-value p-value OR (95% CI)
Bladder D1cc 0.144* 0.233 -
Bladder D2cc 0.098* 0.231 -
Bladder D25 ≥ 30% PD 0.023* 0.029** 29.56 (1.41-621.51)
Bladder V75 0.018* 0.277
Bladder V80 0.034* 0.380 -
Bladder V75 (cc) 0.260 - -
Bladder V80 (cc) 0.371 - -
Bladder Neck D0.1cc 0.747 - -
Bladder Neck V80 0.450 - -
Bladder Neck V80 (cc) 0.718 - -
PUS D0.1cc 0.284 - -
PUS D30 0.647 - -
PUS V110 0.434 - -
PUS V110 (cc) 0.441 - -
PUM D0.1cc 0.25 - -
PUM D30 0.299 - -
PUM V110 0.962 - -
PUM V110(cc) 0.079* 0.056 -
PUI D0.1cc 0.363 - -
PUI D30 0.645 - -
PUI V110 0.745 - -
PUI V110 (cc) 0.371 - -
Urethra Membranous D0.1cc 0.622 - -
Urethra Membranous D0.5cc 0.043* 0.757 -
Urethra Membranous D30 0.309 - -
Urethra Membranous V100 0.063* 0.155 -
Urethra Membranous V100 (cc) 0.119* 0.456 -
TRUS volume ≥ 40 cc 0.036* 0.426 -
Qmax < 10 ml/s 0.046* 0.048** 8.71 (1.02-74.46)
Urinary residue ≥ 30 ml 0.827 - -
IPSS ≥ 10 0.121* 0.016** 33.84 (1.91-600.55)
Needles ≥ 17 0.084* 0.115 -
PTV Volume ≥ 50 cc 0.132* 0.682 -
Urethra length ≥ 50 mm 0.509 - -
Age ≥ 70 year 0.663 - -
* Statistically signicant (p-value <0.2): Pre-selection;
**Statistically signicant (p-value ≤0.05);
PUS = Prostatic Urethra Superior; PUM = Prostatic Urethra MID;
PUI = Prostatic Urethra Inferior; UM = Membranous Urethra;
OR = Odd ratio; 95% CI = 95% Condence interval.
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Table D.12: Completed Result of TEST.A14. - Automatic MI
Univariable Multivariable
Variable p-value p-value OR (95% CI)
Bladder D1cc 0.144* 0.737 -
Bladder D2cc 0.098* 0.855 -
Bladder D25 ≥ 30% PD 0.023* 0.148 -
Bladder V75 0.018* 0.022** 5.61 (1.29-24.41)
Bladder V80 0.034* 0.199 -
Bladder V75 (cc) 0.260 - -
Bladder V80 (cc) 0.371 - -
Bladder Neck D0.1cc 0.747 - -
Bladder Neck V80 0.450 - -
Bladder Neck V80 (cc) 0.718 - -
PUS D0.1cc 0.284 - -
PUS D30 0.647 - -
PUS V110 0.434 - -
PUS V110 (cc) 0.441 - -
PUM D0.1cc 0.25 - -
PUM D30 0.299 - -
PUM V110 0.962 - -
PUM V110 (cc) 0.079* 0.056 -
PUI D0.1cc 0.363 - -
PUI D30 0.645 - -
PUI V110 0.745 - -
PUI V110 (cc) 0.371 - -
UM D0.1cc 0.622 - -
UM D0.5cc 0.043* 0.266 -
UM D30 0.309 - -
UM V100 0.063* 0.163 -
UM V100 (cc) 0.119* 0.225 -
TRUS volume ≥ 40 cc 0.036 0.103 -
Qmax < 10 ml/s 0.046* 0.027** 8.44 (1.27-56.22)
Urinary residue ≥ 30 ml 0.827 - -
IPSS ≥ 10 0.121* 0.026** 13.59 (1.37-134.76)
Needles ≥ 17 0.084* 0.152 -
PTV Volume ≥ 50 cc 0.132* 0.604 -
Urethra length ≥ 50 mm 0.509 - -
Age ≥ 70 year 0.663 - -
* Statistically signicant (p-value <0.2): Pre-selection;
**Statistically signicant (p-value ≤0.05);
PUS = Prostatic Urethra Superior; PUM = Prostatic Urethra MID;
PUI = Prostatic Urethra Inferior; UM = Membranous Urethra;
OR = Odd ratio; 95% CI = 95% Condence interval.
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Table D.13: Completed Result of TEST.A14. - MCMC MI
Univariable Multivariable
Variable p-value p-value OR (95% CI)
Bladder D1cc 0.144* 0.223 -
Bladder D2cc 0.098* 0.231 -
Bladder D25 ≥ 30% PD 0.023* 0.029** 29.56 (1.41-621.51)
Bladder V75 0.018* 0.277 -
Bladder V80 0.034* 0.380 -
Bladder V75 (cc) 0.260 - -
Bladder V80 (cc) 0.371 - -
Bladder Neck D0.1cc 0.747 - -
Bladder Neck V80 0.450 - -
Bladder Neck V80 (cc) 0.718 - -
PUS D0.1cc 0.284 - -
PUS D30 0.647 - -
PUS V110 0.434 - -
PUS V110 (cc) 0.441 - -
PUM D0.1cc 0.250 - -
PUM D30 0.299 - -
PUM V110 0.962 - -
PUM V110 (cc) 0.079* 0.056 -
PUI D0.1cc 0.363 - -
PUI D30 0.645 - -
PUI V110 0.745 - -
PUI V110 (cc) 0.371 - -
UM D0.1cc 0.622 - -
UM D0.5cc 0.043* 0.757 -
UM D30 0.309 - -
UM V100 0.063* 0.155 -
UM V100 (cc) 0.119* 0.456 -
TRUS volume ≥ 40 cc 0.036* 0.426 -
Qmax < 10 ml/s 0.046* 0.048** 8.71 (1.02-74.46)
Urinary residue ≥ 30 ml 0.827 - -
IPSS ≥ 10 0.121* 0.016** 33.84 (1.91 -600.55)
Needles ≥ 17 0.084* 0.115 -
PTV Volume ≥ 50 cc 0.132* 0.682 -
Urethra length ≥ 50 mm 0.509 - -
Age ≥ 70 year 0.663 - -
* Statistically signicant (p-value <0.2): Pre-selection;
**Statistically signicant (p-value ≤0.05);
PUS = Prostatic Urethra Superior; PUM = Prostatic Urethra MID;
PUI = Prostatic Urethra Inferior; UM = Membranous Urethra;
OR = Odd ratio; 95% CI = 95% Condence interval.
Appendix E
Complete results of Chapter 5: Rectal Bleeding
Project
Table E.1: Complete result of Mann-Whitney test.
Rectum Variables RB (n=15) no-RB (n=30) Rectum Wall Variables RB (n=15) no-RB (n=30)
Cranial Part Median Median p-value Cranial Wall Part Median Median p-value
Dmean (% of PD) 11.90 8.90 0.028* Dmean (% of PD) 11.79 8.48 0.010*
D1cc (% of PD) 15.39 15.35 0.665 D1cc (% of PD) 16.13 14.45 0.132
D2cc (% of PD) 13.95 13.79 0.665 D2cc (% of PD) 13.69 12.23 0.107
D10 (% of PD) 15.50 13.38 0.107 D10 (% of PD) 17.57 13.56 0.028*
D25 (% of PD) 13.67 10.69 0.034* D25 (% of PD) 13.61 10.03 0.011*
V10 (cc) 5.33 7.77 0.682 V10 (cc) 4.93 4.585 0.360
V20 (cc) 0.09 0.05 0.672 V20 (cc) 0.24 0.05 0.183
V30 (cc) - - - V30 (cc) - - -
V40 (cc) - - - V40 (cc) - - -
Caudal Part Caudal Wall Part
Dmean (% of PD) 26.63 26.53 0.886 Dmean (% of PD) 26.53 27.63 0.962
D1cc (% of PD) 71.96 73.96 0.312 D1cc (% of PD) 71.96 73.98 0.324
D2cc (% of PD) 64.98 67.29 0.413 D2cc (% of PD) 64.95 66.44 0.386
D10 (% of PD) 50.55 51.32 0.427 D10 (% of PD) 58.48 60.63 0.258
D25 (% of PD) 34.45 34.97 0.613 D25 (% of PD) 34.52 37.20 0.248
V10 (cc) 51.27 48.87 0.981 V10 (cc) 24.54 23.17 0.373
V20 (cc) 32.78 31.40 0.613 V20 (cc) 14.72 14.63 0.942
V30 (cc) 19.05 17.27 0.895 V30 (cc) 8.13 9.32 0.516
V40 (cc) 10.46 10.10 0.923 V40 (cc) 5.21 6.21 0.605
V75 (cc) 0.70 0.90 0.253 V75 (cc) 0.70 0.89 0.238
V80 (cc) 0.21 0.43 0.323 V80 (cc) 0.23 0.41 0.360
V90 (cc) 0.00 0.02 0.481 V90 (cc) 0.00 0.02 0.481
Anus Anus Wall Part
Dmean(% of PD) 14.13 14.63 0.523 Dmean (% of PD) 14.34 14.42 0.596
D1cc(% of PD) 21.61 22.13 0.754 D1cc (% of PD) 20.21 20.76 0.754
D2cc (% of PD) 19.06 19.02 0.791 D2cc (% of PD) 16.97 17.26 0.754
D10 (% of PD) 20.32 21.71 0.773 D10 (% of PD) 20.47 21.82 0.700
D25 (% of PD) 16.32 17.77 0.700 D25 (% of PD) 16.27 17.62 0.665
V10 (cc) 9.70 8.39 0.500 V10 (cc) 5.77 5.82 0.571
V20 (cc) 1.53 1.59 0.691 V20 (cc) 1.04 1.15 0.718
V30 (cc) 0.03 0.04 0.844 V30 (cc) 0.03 0.03 0.844
V40 (cc) - - - V40 (cc) - - -
Abbreviations: * Statistically signicant.
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